

**UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS**

In re: PHARMACEUTICAL INDUSTRY  
AVERAGE WHOLESAL PRICE  
LITIGATION

MDL No. 1456

Civil Action No. 01-12257-PBS

Subcategory No. 01-11337-PBS

**THIS DOCUMENT RELATES TO:**

Hon. Patti B. Saris

*United States of America ex rel. Ven-a-Care of the Florida Keys, Inc. v. Dey, Inc., et al.*, Civil Action No. 05-11084-PBS; and

*United States of America ex rel. Ven-a-Care of  
the Florida Keys, Inc. v. Boehringer  
Ingelheim Corp., et al.*, Civil Action No. 07-  
10248-PBS

**UNITED STATES' SUBMISSION OF WITNESS LIST, DEPOSITION  
WITNESSES, AND EXHIBIT LIST PURSUANT TO FED. R. CIV. P. 26(a)(3)(A)**

Pursuant to Fed. R. Civ. P. 26(a)(3)(A) and the Court's Pretrial Order, the United States hereby discloses: (i) the names of witnesses it expects to call, or may call, at trial (the United States' Witness List, Exhibit 1, hereto); (ii) the names of the witnesses whose deposition testimony it expects to present, or may, present at trial (Exhibit 2, hereto); and (iii) the exhibits it expects to introduce, or may introduce, at trial (the United States' Exhibit List, Exhibit 3, hereto). Although the names of the witnesses whose deposition testimony the United States expects to present, or may, present at trial are attached at Exhibit 2, pursuant to the Revised Proposed Pretrial Schedule proposed jointly by the parties on March 8, 2010 (Master Dkt #6613, Sub. #709), the United States is serving, but not filing, the actual designations of deposition testimony it expects to present at trial. The parties have proposed to file with the Court the designations of testimony once counter-designations and counter-counter designations have been made.

In addition to the disclosures set forth in the Witness List attached hereto, the United States may call to testify at trial any witness whom a Defendant has identified in its witness list or for whom a Defendant has designated deposition testimony. The United States further reserves the right to call any witness whose deposition testimony the United States has designated, if the Court determines that the deposition testimony is inadmissible under Fed. R. Civ. P. 32.

With respect to the United States' Exhibit List, the inclusion of a document as an exhibit does not constitute an admission by Plaintiffs that the document is admissible in evidence, and the United States reserves the right to object to its admission in evidence if offered by a Defendant.

Respectfully submitted,

For the United States of America,

CARMEN M. ORTIZ  
UNITED STATES ATTORNEY

/s/ George B. Henderson, II  
George B. Henderson, II  
Barbara Healy Smith  
James J. Fauci  
Assistant U.S. Attorneys  
United States Courthouse  
Suite 9200, 1 Courthouse Way  
Boston, MA 02210  
Phone: (617) 748-3272  
Fax: (617) 748-3971

TONY WEST  
ASSISTANT ATTORNEY GENERAL

/s/ Laurie A. Oberembt  
Joyce R. Branda  
Daniel Anderson  
Renée Brooker  
Justin Draycott  
Rebecca Ford  
Laurie A. Oberembt  
Civil Division  
Commercial Litigation Branch  
P. O. Box 261  
Ben Franklin Station  
Washington, D.C. 20044  
Phone: (202) 307-1088  
Fax: (202) 307-3852

For the relator, Ven-A-Care of the Florida  
Keys, Inc.,

James J. Breen  
The Breen Law Firm, P.A.  
5755 Northpoint Parkway  
Suite 260  
Alpharetta, GA 30022  
Phone: (770) 740-0008  
Fax: (770) 740-9109

Dated: March 16, 2010

CERTIFICATE OF SERVICE

I hereby certify that I have this day caused an electronic copy of the above document to be served on all counsel of record via electronic service pursuant to Paragraph 11 of Case Management Order No. 2 by sending a copy to LexisNexis File & Serve for posting and notification to all parties.

Dated: March 16, 2010

/s/ George B. Henderson, II  
George B. Henderson, II

# **Exhibit 1**

to

United States' Submission of Witness List, Deposition Witnesses,  
and Exhibit List Pursuant to Fed. R. Civ. P. 26(a)(3)(A)

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Name	Address/Phone # (if not previously provided)	Affiliation	Intent to Call	Objection
Bahr, Debra	3561 Hunters Green Way, Lexington, KY 40509. Contact through counsel: Robert S. Libman, Miner, Barnhill & Galland, 14 West Erie, Chicago, IL 60654 / (312) 751-1170. rlibman@lawmbg.com	State - Kentucky	May Call	
Berenson, Robert	Urban Institute, 2100 M Street, N.W., Washington, DC 20037. Contact through counsel for the United States: Rebecca Ford (202) 514-1511.	HHS	May Call	
Berkle, Sheldon	5745 Grande Reserve Way, Unit 504, Naples, FL 34110-2353 / (239) 348-9218. OR 20 Deerfield Road, Brookfield, CT 06804-1304 / (203) 775-8765.	Boehringer	May Call	
Booth, Charles	8024 Ridgely Oak Road, Baltimore, MD 21234. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Bronstein, Debra	11955 E LA Posada Circle, Scottsdale, AZ / (480) 502-8135.	Dey	May Call	
Buto, Kathleen	2032 North Stafford Street, Arlington, VA 22207. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Butt, Mark-Richard	New York State Department of Health, 99 Washington Avenue, Suite 720, Albany, NY 12210. Contact through counsel: Heidi A. Wendel, Special Deputy Attorney General, 120 Broadway, 13th Floor, New York, NY 10271 / (212) 417-5250.	State - New York	Expect to Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Cecil, Rebecca	15013 Glendower Drive, Louisville, KY 40245. Contact through counsel: Robert S. Libman, Miner, Barnhill & Galland, 14 West Erie, Chicago, IL 60654 / 312-751-1170. rlibman@lawmbg.com	State- Kentucky	May Call	
Chesser, Paul	11300 North Rodney Parham Road, Suite 205, Little Rock, AR 72212. Contact through counsel for the United States: Rebecca Ford / (202) 514- 1511.	HHS-OIG	May Call	
Ciarelli, Gregg	8 Old Purdy Station Road, Newtown, CT 06470- 2461 / (203) 426-6363. <u>OR</u> 29 Windwood Road, Bernardsville, NJ 07924-1821 / (908) 696-8586.	Boehringer	May Call	
Cioppa, Carl	Office of Health Insurance Programs, Bureau of Pharmacy Policy and Operations, 99 Washington Ave., Suite 720m, Albany, NY 12210-2806. Contact through counsel: Gregor N. Macmillan, Director, Bureau of Health Insurance Programs, Division of Legal Affairs, New York State Department of Health, Corning Tower - 24th floor Empire State Plaza, Albany, NY 12238 / (518) 408-1495. gnm01@health.state.ny.us	State - New York	May Call	
Clifford, Margaret	Contact through counsel: Jonathan Gallo, 129 Pleasant St., Brown Bldg, 2d Floor, Concord NH 03301 / (603) 271-4758.	State - New Hampshire	Expect to Call	
Cobo, Luis	615 1/2 Duval Street, Unit 4, Key West, FL 33040. Contact through counsel: James J. Breen / (770) 740-0009.	Relator	May Call	
Denemark, Cynthia	3 Timber Ridge Court, Newark DE 19711. Contact through counsel: Ann Woolfolk / (302) 577-8350.	State - Delaware	Expect to Call	
DeParle, Nancy Ann	4229 Leland Street, Chevy Chase, MD 20815. Contact through counsel for the United States: Rebecca Ford (202) 514-1511.	HHS	May Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Dew, Ian	Steck Consulting, LLC, 1730 Rhode Island Ave, N.W., Suite 507, Washington, DC 20036. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Consultant	Expect to Call	
Dipaola, Edward	14 Fernbrook Drive, Brookfield CT 06804 / (203) 740-9822.	Boehringer	Expect to Call	
Dubberly, Jerry	Contact through counsel: Michelle Townes, Office of the Attorney General, 40 Capitol SQ, S.W., Atlanta, GA 30334 / (404) 656-3446. mtownes@law.ga.gov	State - Georgia	May Call	
Duggan, Mark	University of Maryland, Department of Economics, 3105 Tydings Hall, College Park, MD 20742. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Expert	Expect to Call	
Duzor, Deidre	2601 Lighthouse Lane, Baltimore, MD 21244. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Ellis, Robert	Polaris Road, Tahoe City, CA / Phone Number - Unlisted. <u>OR</u> EG Capital, LLC 3019 Oakham Drive, San Ramon, CA. <u>OR</u> Frontline Strategic Consulting, 1850 Gateway Drive, San Mateo, CA 94404-4060 / (650) 525-1505.	Dey	May Call	
Fan, Kristen	7500 Security Boulevard, Baltimore, MD 21244 / (410) 786-3000. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	Expect to Call	
Farrand, Lise	Health and Human Services, Office of Medicaid Business and Policy, 129 Pleasant Street, Annex Building, Concord, NH 03301. Contact through counsel: Jonathan Gallo, 129 Pleasant St., Brown Bldg, 2d floor, Concord NH 03301 / (603) 271-4758.	State - New Hampshire	Expect to Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Galles, Todd Christopher	215 Alchemy Way, Napa, CA 94558 / (707) 255-2565 or (707) 226-2565.	Dey	Expect to Call	
Gaston, Sue	9011 Thugmorton Road, Baltimore, MD 21234. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Gerstenberg, Werner	Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 / (203) 798-9988. OR 112 Chestnut Hill Road, Stanford, CT 06903-4003 / (203) 322-5261.	Boehringer	May Call	
Gorospe, James Kevin	Health Management Associates, 555 Capitol Mall Suite 260, Sacramento, CA 95814 / (916) 446-4601 ext. 427. kgorospe@healthmanagement.com	State - California	Expect to Call	
Guerrant, Timothy	Contact through counsel: Bruce A. Roby, Waggener, Arterburn & Standiford, 1400 S.W. Topeka Blvd., Topeka, KS 66612-1819 / (785) 235-2361. barlaw@sbcglobal.net	Plaintiffs' Consultant	Expect to Call	
Gustafson, Tom	Arnold and Porter, 555 Twelfth Street, N.W., Washington, DC 20004. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Helton, Carolyn	Carolyn Helton, CIGNA, 2 Vantage Way, Nashville, TN 37228, (615) 782-4500. To be contacted through carrier counsel: Michael Wade, Office of Counsel, CIGNA Government Services, Two Vantage Way, Nashville, TN 37228 / (860) 226-2457. Michael.Wade@CIGNA.com	Carrier - Cigna (30(b)(6))	Expect to Call	
Homar, Roxanne	Wyoming Department of Health, Suite 259A, Qwest Bldg., 6101 Yellowstone Road, Cheyenne, WY 82002. Contact through counsel: K. Shaun Wilkerson, State of Wyoming Attorney General's Office, 123 Capitol Bldg. Cheyenne, WY 82002 / (307) 777-3730.	State - Wyoming	May Call	



## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Jeffrey, Paul L	Contact through counsel: Peter Mullin, Assistant Attorney General, Office of the Attorney General, One Ashburton Place, Boston, MA 02108 / (617) 963-2622.	State - Massachusetts	May Call	
Jones, T. Mark	615 1/2 Duval Street, Unit 4, Key West, FL 33040. Contact through counsel: James J. Breen / (770) 740-0009.	Relator	May Call	
King, Colleen	75 Kelly Avenue, Wilkes-Barre, PA 18705 / (570) 825-4716.	Carrier	Expect to Call	
Knerr, Kris	Contact through counsel: Bruce A. Roby, Waggener, Arterburn & Standiferd, 1400 S.W. Topeka Blvd., Topeka, KS 66612-1819 / (785) 235-2361. barlaw@sbcglobal.net	Plaintiffs' Consultant	Expect to Call	
Leonetti, Mike	353 Beecher Drive, Southbury, CT 04688-3911 / (203) 264-8609.	Boehringer	May Call	
Lockwood, John	615 1/2 Duval Street, Unit 4, Key West, FL 33040. Contact through counsel: James J. Breen / (770) 740-0009.	Relator	May Call	
Marmor, Theodore R	Yale School of Management, 135 Prospect Street, P. O. Box 208200, New Haven, CT 06520-8200. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Expert	May Call	
McIntyre, James F.	Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 / (203) 798-9988.	Boehringer	May Call	
O'Connor, Brien	Ropes & Gray, One International Place, Boston, MA 02110-2624 / (617) 951-7385.	Other Third Party	May Call	
Ormond, Patrick	U.S. Attorney's Office, 1 Courthouse Way, Suite 9200, Boston MA 02210. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	USAO - Massachusetts	Expect to Call	
Paoletto, Lesli	Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 / (203) 798-9988.	Boehringer	May Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Parker, James	Illinois Department of Healthcare and Family Services, 201 South Grand Avenue East, Springfield, Illinois. Contact through counsel: Jeanette G. Badrov, Illinois Department of Healthcare and Family Services, 401 South Clinton Street, Sixth Floor, Chicago, IL 60607 / (312) 793-8620.	State - Illinois	Expect to Call	
Perri, Matthew	Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Athens, GA 30602. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Expert	Expect to Call	
Platt, Simon	60 State Street, Suite 3500, 35th Floor, Boston, MA 02109. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Consultant	Expect to Call	
Ragone, Linda	Suite 436, Public Ledger Building, 150 S. Independence Mall West, Philadelphia, PA 19106-3499. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS-OIG	Expect to Call	
Reed, Larry	7500 Security Boulevard, Baltimore, MD 21244. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Rugg, Ann	Vermont Department of Health, 108 Cherry Street, Burlington, VT 05402. Contact through counsel: Michael N. Donofrio, Assistant Attorney General, Office of the Attorney General, 109 State Street, Montpelier, VT 05609 / (802) 828-6906. mdonofrio@atg.state.vt.us	State - Vermont	May Call	
Russillo, Thomas	17 Vista Montemar, Laguna Niguel, CA 92677 / (949) 542-4042. <u>OR</u> 14 Old Ranch Road, Laguna Niguel, CA 92677 / (330) 995-6531.	Boehringer	May Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Schondelmeyer, Stephen	PRIME Institute, 7-159 Weaver-Densford Hall, 308 Harvard Street, S.E., Minneapolis, MN 55455, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	Plaintiffs' Expert	Expect to Call	
Scully, Thomas	Alston + Bird, 950 F Street, N.W., Washington, D.C. 20004-1404 / (202) 756-3459.	HHS	May Call	
Selenati, Helen	106 Mendocino Way, Redwood City, CA 94065 / (650) 596-0807.	Dey	Expect to Call	
Stone, Robin Kruesh	Palmetto GBA, Carolina Research Park, 17 Technology Circle, Columbia, SC 29203 / (803) 763-1098. robin.stone@palmettogba.com	Carrier - Palmetto GBA	Expect to Call	
Sykora, Robert C.	205 Woodcliff Ct., Suwanee, GA 30024-5455 / (678) 947-6555.	Boehringer	Expect to Call	
Thompson, Don	7500 Security Boulevard, Baltimore, MD 21244 / (410) 786-3000. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	Expect to Call	
Tupa, Edward J.	130 County Road, P.O. Box 1094, Granby, CO 80446 / (970) 887-3011.	Boehringer	Expect to Call	
Turner, Shannon	Contact through counsel: Robert S. Libman, Miner, Barnhill & Galland, 14 West Erie, Chicago, IL 60654 / (312) 751-1170. rlibman@lawmbg.com	State - Kentucky	May Call	
Uhl, Ross	28499 Ono Blvd., Orange Beach, AL 36561 / (251) 981-1967.	Dey	Expect to Call	
Vaccaro, Edward J.	Contact through counsel: Zoe J. McLaughlin, Department of Law and Public Safety, 25 Market Street, Trenton, NJ 08625 / (609) 341-3689.	State - New Jersey	May Call	
Via, Thomas	12065 Silver Shore Court, Indianapolis, IN 46236 / (317) 826-8409.	Boehringer	Expect to Call	

## Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456

## Exhibit 1 - The United States' Witness List

Vito, Robert	150 S. Independence Mall West, Public Ledger Bldg, Philadelphia, PA 19106-9111. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS-OIG	May Call	
Vladeck, Bruce	38360 West 36th Street, New York, NY, 10018. Contact through counsel for the United States: Rebecca Ford / (202) 514-1511.	HHS	May Call	
Waterer, Judy	Roxane Laboratories, 300 Northfield Road, Bedford OH, 44146 / (614) 276-4000. judy.waterer@boehringer-ingelheim.com	Boehringer	May Call	
Weeks, Lisa	The North Carolina Department of Health and Human Services, Division of Medical Assistance, 1985 Umstead Drive, Raleigh, North Carolina. Contact through counsel: Tracy J. Hayes, State of North Carolina, Dept. of Justice, 114 W. Edenton Street, P.O. Box 629, Raleigh, NC 27602-0629 / (919) 716-6840. tjhayes@ncdoj.gov	State - North Carolina	May Call	
Wells, Jerry	154 Royster Drive, Crawfordville, FL 32327. Contact through Gretchen H. Wallace, Assistant Attorney General, Office of the Attorney General, PL-101, The Capitol, Tallahassee, FL 32399-1050 / (850) 414-3600.	State - Florida	May call	
Winter, Raymond	Chief, Civil Medicaid Fraud Division, P.O. Box 12548, Austin, TX 78711-2548 / (512) 936-1709.	State - Texas	Expect to Call	

## **Exhibit 2**

to

United States' Submission of Witness List, Deposition Witnesses,  
and Exhibit List Pursuant to Fed. R. Civ. P. 26(a)(3)(A)

**Civil Action Nos. 05-11084-PBS, 07-10248-PBS, MDL No. 1456**  
**Exhibit 2 - List of Witnesses for Whom the United States**  
**Has Designated Deposition Testimony<sup>1</sup> / <sup>2</sup>**

Witness Name	Affiliation
Barnes, Roy	Dey
Berenson, Robert*	HHS
Berkle, Sheldon*	Boehringer
Breen, James	First DataBank
Bridges, Suzette	State-Arkansas
Bronstein, Debra*	Dey
Buto, Kathleen*	HHS
Carr-Hall, Colin	Boehringer
Chapman, Allen	State-Colorado
Chmielewski, Donald	Boehringer
Ciarelli, Gregg P.*	Boehringer
Collie Daulong, Cynthia	Dey
Comston, Don	Boehringer
Davis, Marilyn	FDB
Davis, Myra	State-Washington
DeParle, Nancy*	HHS
Dusek, Alex	Boehringer
Duy, Frederick	Boehringer
Duzor, Deidre*	HHS
Eiler, Cheryl - 30(b)(6)	Carrier - Administar Federal
Ellis, Robert*	Dey
Erick, Matthew	Cardinal Health
Factor, Saul	McKesson
Fagrell-Gmeiner, Eve	Dey
Feldman, Richard	Boehringer
Gist, James	Dey
Gordon, Dawn	Third Party
Gustafson, Tom*	HHS
Hill, William	Dey
Hirschmann, Joseph	FDB

---

<sup>1</sup> The corresponding designated deposition transcript pages are referenced in a separate pre-trial submission being exchanged by the parties on the date of this filing, and to be subsequently filed with the Court.

<sup>2</sup> An \* following the witness's name indicates that the witness is also designated on Plaintiff's Witness List as a "May Call if the Need Arises" at trial.

Homar, Roxane*	State-Wyoming
Jackson, Carrie-Jean	Dey
Johnston, Russell	Dey
King, James	Boehringer
Kramer, Sandra	State-Michigan
Kustra, Kathleen	State-Kentucky
Kutner, Deborah	Boehringer
Lyle, Don	Cardinal
Marrs, Pamela	Dey
Mayhew, Cheri	Boehringer
McIntyre, James*	Boehringer
Minne, Kristen	Thompson PDR
Morgan, Patricia Kay	FDB
Mozak, Robert	Dey
Paoletti, Lesli*	Boehringer
Pope, Mark	Boehringer / Dey
Powers, John	Boehringer
Reich, Ron	Cardinal Health
Rice, Charles	Dey
Ricks-Bey, Michael	Dey
Rowenhorst, James Allen	Boehringer
Rugg, Ann*	State-Vermont
Russillo, Thomas*	Boehringer
Shaffer, Mark	Boehringer
Sharp, Michael	State-Indiana
Smith, Dennis	HHS
Tavolaro, Anthony	Boehringer
Tetzner, Hermann	Boehringer
Tipton, Bruce	Dey
Upp, Richard	Dey
Vaccaro, Edward*	State-New Jersey
Vladeck, Bruce*	HHS
Walker, Gary	Dey
Warren, Neil	Cardinal
Waterer, Judy*	Boehringer
Weeks, Lisa*	State-North Carolina

# **Exhibit 3**

to

United States' Submission of Witness List, Deposition Witnesses,  
and Exhibit List Pursuant to Fed. R. Civ. P. 26(a)(3)(A)



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00001	12/23/1998	Bid Price Worksheet	Mozak Ex. 86, 11/1/01	DL-TX-0007888	Expect	
00002	5/30/1995	Memo from Helen Burnham re Albuterol WAC pricing	Rice Ex. 72, 10/30/01	n/a	Expect	
00003	12/11/1995	Memo from Ross Uhl re Gerimed and RxMed proposals	Rice Ex. 74, 10/30/01	DL1584	Expect	
00004	10/14/1997	Memo from Ross Uhl re: Gerimed Rebate Clarification	Mozak Ex. 91, 11/1/01	DL-TX-0020864	Expect	
00005	8/26/1996	Ipratropium Bromide Launch Manual	Galles, Ex. 274, 3/1/06	DL-TX-0076144	Expect	
00006	8/12/1993	Memo from Carrie Jackson re Medicare	Mozak Ex. 230, 4/30/02	DL-0050001	Expect	
00007	2/2/1994	Memo from Carrie Jackson re Medicare/Medicaid/Formulary Update	Mozak Ex. 231, 4/30/02	DL-0050028	Expect	
00008	07/??/1998	Memo from Susan Rhodes re Award	Mozak, Ex. 233, 4/30/02	DL-TX-0020678	Expect	
00009	6/11/1999	Ltr from Russell Johnston re Proposed Contract Modification	Mozak, Ex. 234, 4/30/02	DL-TX-0020527	Expect	
00010	9/13/1999	Ltr from Russell Johnston re: CFI of New Jersey, Inc. & Central Fill, Inc. of New Jersey Inc. and Central FILL, Inc.	Mozak, Ex. 236, 4/30/02	DL-TX-0013451	Expect	
00011	7/14/1999	Ltr from Russell Johnson re: Purchase & Rebate Agreement Proposal Between CFI of New Jersey, Inc. & Central Fill, Inc.	Mozak, Ex. 237, 4/30/02	DL-TX-0013503	Expect	
00012	2/5/1999	Memo from Jackie Perkins re: Bid Price Worksheets	Mozak Ex. 245, 4/30/02	DL-BO-118079	Expect	
00013	12/4/1995	Texas Exhibit 342, fax to First DataBank	Mozak Ex. 342, 11/6/02	DL-TX-0090591	May	
00014	1/21/1995	Rick Upp manager's weekly recap	Mozak Ex. 344, 11/6/02	DL-TX-0407111	May	
00015	8/3/1995	Proposal to Managed Healthcare Assoc	Gist Ex. 328, 11/5/02	DL-TX-0029703	Expect	
00016	3/4/1996	Memo from Todd Galles re: New Product Announcement	Gist Ex. 338, 11/5/02	DL-TX-0076226	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00017	2/24/1992	Memo from Robert Mozak to Pam Marrs, Charles Rice, Jean-Pierre Termier re: Albuterol pricing strategies	Marrs Ex. 022, 5/15/08	DL-TX-0090851	Expect	
00018	02/??/1995	Building on Success presentation; Albuterol Worksheets	Galles Ex. 460, 2/6/03	DL-TX-0090875	Expect	
00019	10/6/1997	OIG Subpoena to Dey Labs	Mozak Ex. 555, 3/13/03	n/a	Expect	
00020	7/27/2000	OIG Subpoena to Dey Labs	Mozak Ex. 556, 3/13/03	n/a	Expect	
00021	7/11/2001	Memo from Mike Wilson re Caremark	Mozak Ex. 557, 3/13/03	DL-TX-0134058	Expect	
00022	1/11/2002	Memo from Bob Mozak re Albuterol & Ipratropium at Managed HealthCare	Mozak Ex. 558, 3/13/03	DL-TX-0164082	Expect	
00023	10/24/2000	Ltr from Janet Penner to Joseph Ruhmel	Johnston Ex. 55, 12/11/08	DL-TX-0159097	Expect	
00024	02/??/1995	Reimbursement Comparison Worksheet	Galles Ex. 461, 2/6/03	DL-TX-076254	Expect	
00025	6/4/1995	Memo from Rick Upp re Work-With	Gist Ex. 329, 11/5/02	DL-TX-0407069	Expect	
00026	5/1/1998	Ltr re: Dey Laboratories Sales	Rice Ex. 349, 11/7/02	DL-TX-0082805	Expect	
00027	3/18/2002	Memo from Charles Rice re Advanced PCS Contract Membership Listings	Tate Ex. 475, 2/7/03	DL-TX-0091114	Expect	
00028	6/19/2001	Memo from Mike Wilson re Caremark	Rice Ex. 569, 3/24/03	DL-TX-0064705	May	
00029	7/11/2001	Dey Bid Price Worksheet	Rice Ex. 570, 3/24/03	DL-TX-0134058	May	
00030	4/5/1995	Memo from Todd Galles re Marketing Update: AWP Pricing & Profit Gain	Galles Ex. 462, 2/6/03	DL-TX-0091109	Expect	
00031	9/28/1994	Memo from Robert Robert F. Mozak re Cromolyn Sales Update	Selenati Ex. 40, 5/4/03	DL-TX-0161590	Expect	
00032	10/15/1993	Memo from Robert F. Mozak re	Rice Ex. 578, 3/24/03	DL-TX-0091106	Expect	
00033	1/1/1994	Abridged Marketing Plan	Gallas Ex. 261, 2/28/06	DL-TX-0090967	Expect	
00034	TBD	Tate Exhibit 471 -- Retail Questions	Tate Ex.471, 2/7/03	DL-TX-0090869	Expect	
00035	8/4/1995	Sales Call Protocol	Galles Ex. 271, 3/1/06	DL-TX-0091390	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00036	1/24/1994	Ross Uhl Re: Working a Homecare	Uhl Ex. 778, 2/24/03	DL-TX-0075972	Expect	
00037	8/12/1994	Memo from Carrie Jackson re State of Florida Medicaid Program	Uhl Ex. 777, 2/24/03	n/a	Expect	
00038	2/3/1995	Memo from Robert Mozak re Building of	Hill Ex. 9, 11/11/08	DL-TX-0096741	Expect	
00039	12/11/1995	Memo from Ross Uhl re Gerimed & RxMed Proposals	Tipton Ex. 489, 2/13/03	DL1584	Expect	
00040	1/4/1996	Memo from Ross Uhl Re Gerimed and Rx Med Promotion	Tipton Ex. 490, 2/13/03	DL1215	Expect	
00041	1/4/1996	Memo from Ross Uhl re: Managed HealthCare Associates Promotion	Tipton Ex. 491, 2/13/03	DL-TX-0029646	Expect	
00042	4/8/1996	Memo from Ross Uhl re: Gerimed and Rx Med Promotion	Tipton Ex. 492, 2/13/03	DL-TX-0046136	Expect	
00043	10/14/1997	Memo from Ross Uhl re Gerimed Rebate Clarification	Uhl Ex. 779, 2/24/03	DL-TX-0020864	Expect	
00044	8/3/1995	Fax from Cindy Daulong re: Reimbursement Comparison Worksheet	Uhl Ex. 780, 2/24/03	DL-TX-0029712	Expect	
00045	3/25/1999	Dey Bid Price Worksheet	n/a	DL-TX-0041085	Expect	
00046	8/11/1997	Dey Bid Price Worksheet	n/a	DL-BO-085585	Expect	
00047	6/15/1997	Dey Bid Price Worksheet	n/a	DL-BO-086434	Expect	
00048	10/25/1995	Ltr from Todd Galles re Redbook	Galles Ex. 467, 2/6/03	DL-TX-010325	May	
00049	1995	Reimbursement Comparison Worksheet	Barnes Ex. 010, 10/30/08	DL-TX-0076254	Expect	
00050	1/31/1995	Dey Lab Advertising Approval Record	Marrs Ex. 37, 3/11/05	DL-TX-0170961	Expect	
00051	11/??/1995	Marketing Launch Plan	n/a	DL-TX-0093357	Expect	
00052	3/4/1996	Memo from Todd Galles re new product announcement	Selenati Ex. 44, 5/4/05	DL-TX-0076226	Expect	
00053	11/13/1996	Memo from Todd Gales re Albuterol Inhalation Aerosol Refill Launch	n/a	DL-62018	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00054	6/28/1996	Dey Lab Marketing Plan for Ipratropium	n/a	DL-TX-0092981	Expect	
00055	7/23/1999	Memo from Debbie Bronstein re AWP	n/a	DL-TX-0078198	May	
00056	TBD	Ipratropium Pricing guidelines	Galles Ex. 276, 3/1/06	DL-TX-0093185	Expect	
00057	1/13/1997	Memo from Todd Galles re Ipratropium Bromide Inhalation Solution Launch	Rice Ex. 79, 10/30/01	DL0050064	Expect	
00058	1/13/1997	Letter from Todd Galles re: New Production Announcement	Galles Ex. 275, 3/1/06	DL-TX-0093217	Expect	
00059	3/17/1997	Fax from Kristine Lawton re: AWP/WAC	Gmeiner Ex. 623, 1/20/03	DL-010	Expect	
00060	3/20/1997	Fax from Eve Gmeiner Re Dey Product	Gmeiner Ex. 626, 1/20/03	DL-008	Expect	
00061	8/6/1997	Memo from Todd Galles re New Product Launch Ipratropium 30's	n/a	DL-TX-0093567	Expect	
00062	12/29/1998	Letter from Todd Galles re WAC pricing	n/a	DL-TX-0092435	Expect	
00063	7/21/1999	Ltr from Todd Galles re Albuterol Sulfate Inhalation Solution 0.5	n/a	DEY-BO-0236713	May	
00064	1/7/1999	Memo from Todd Galles re Future Medicaid Mailings	Galles Ex. 273, 3/1/06	DL-TX-0092446	May	
00065	8/10/1999	Memo from Todd Galles re Future Medicaid Mailings	n/a	DEY-LABS-0415380	May	
00066	3/1/2000	Memo from Todd Galles re Advance Notification of WAC & AWP Price	Bronstein Ex. 537, 3/11/03	DL-TX-0091963	May	
00067	12/28/2000	Dey Advertising/Promotional Labeling Approval Record	n/a	DL-TX-0091590	May	
00068	7/18/2000	Ltr from Robert Mozak re Albuterol Inhalation Aerosol	Jonston Ex. 52, 12/11/08	DEY-BO0018899	May	
00069	1/4/1996	Memo from Ross Uhl re Managed HealthCare Associates promotion	Galles Ex. 470, 2/6/03	DL-TX-0029646	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00070	4/24/1995	Folder entitled, "Sales Managers Meeting, April 24-27, 1995," with	TX Ex. 741	DL-TX-0097748	Expect	
00071	TBD	Dey Lab Price Evaluation	TX Ex. 742	DL-TX-0105138	Expect	
00072	1/6/1998	Dey Lab 1997 Net Sales by Customer	TX Ex. 743	DL-TX-0099420	Expect	
00073	6/2/1998	Dey Lab 1998 Sales	TX Ex. 746	DL-TX-0099027	Expect	
00074	1/7/1999	Memo from Todd Galles re Future Medicaid Mailings	Gmeiner Ex. 627, 1/20/03	DL-TX-000990	Expect	
00075	1/24/1994	Ross Uhl Working a Homecare Pharmacy	Barnes Ex. 002, 10/30/08	DL-TX-0075972	Expect	
00076	2/5/1995	Agenda, National Sales Meeting	Barnes Ex. 003, 10/30/08	DL-TX-0096749	Expect	
00077	02/??/1995	Albuteral Unit Dose Worksheet	Barnes Ex. 004, 10/30/08	DL-TX-0090875	Expect	
00078	1/1/1994	Cromolyn Sodium Nebulizer Solution Marketing Plan	Barnes Ex. 007, 10/30/08	DL-TX-0090967	May	
00079	4/5/1995	Memo from: Todd Galles re Marketing update: AWP pricing & Profit Gain	Barnes Ex. 008, 10/20/08	DL-TX-0091109	Expect	
00080	2/18/1995	Weekly Sales Recap	Barnes Ex. 013, 10/30/08	DEY-BO-0236794	Expect	
00081	2/25/1995	Weekly Sales Recap	Barnes Ex. 014, 10/30/08	DEY-BO-0273746	Expect	
00082	4/25/1995	Account call record	Barnes Ex. 16-A, 10/3/08	DEY-OIG-0125296	Expect	
00083	4/29/1995	Weekly Sales Recap	Barnes Ex. 017-A, 10/30/08	DEY-BO-0273753	Expect	
00084	3/4/1995	Weekly Sales Recap	Barnes Ex. 018, 10/30/08	DEY-BO-0273747	Expect	
00085	2/10/1995	Account call record	Barnes Ex. 022A, 10/30/08	DEY-BO-0236792	Expect	
00086	2/14/1995	Account call record	Barnes Ex. 023A, 10/30/08	DEY-BO-0236793	Expect	
00087	2/22/1995	Account call record	Barnes Ex. 024A, 10/30/08	DEY-BO-0236795	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00088	3/17/1995	Account call record	Barnes Ex. 025A, 10/30/08	DEY-BO-0236796	Expect	
00089	04/??/1995	Account call record	Barnes Ex. 026A, 10/30/08	DEY-OIG-0125297	Expect	
00090	5/15/1998	Account call record	Barnes Ex. 027A, 10/30/08	DEY-BO-0236798	Expect	
00091	6/7/1995	Account call record	Barnes Ex. 029A, 10/30/08	DEY-BO-0236800	Expect	
00092	10/12/2004	U.S. Complaint Against Roy Barnes	Barnes Ex. 038, 10/30/08		May	
00093	2/2/1994	Memo from Carrie Jackson re Medicare/Medicaid/Formulary Update	n/a	DL-TX-0090898	Expect	
00094	02/??/1992	Dey New Marketing Plan re: Albuterol Sulfate Inhalation Solution	Selenati Ex. 51, 5/5/05	DL-60109	Expect	
00095	5/29/1992	Memo from Helen Burnham re: Albuterol 60's pack and price change	Selenati Ex. 39, 5/4/05	DL-TX-0091112	Expect	
00096	7/20/1993	Memo from Rob Ellis re Copley's	Marrs Ex. 33, 3/11/05	DL-TX-0091094	Expect	
00097	11/5/2001	Audio recording of two voicemail messages from Robert Mozak to Helen Burnham Selenati aka Helen Burnham	FL Ex. 0047	n/a	Expect	
00097A	11/5/2001	Transcript of Depo of Helen Burnham	FL Ex. 0047 transcript	n/a	Expect	
00098	8/31/1993	Ltr from Carrie Jean Jackson re Medicaid Reimbursement	Jackson Ex. 880, 4/18/03	DL-TX-0090867	Expect	
00099	8/12/1994	Memo from Carrie Jackson re: State of Florida Medicaid Program	Mozak Ex. 561, 3/13/03	DL001	Expect	
00100	12/15/1993	Marketing Plan for Cromolyn sodium nebulizer solution	Ellis Ex. 476, 2/10/03	DL-TX-0091006	Expect	
00101	10/2/1992	Memo from Rob Ellis re Monthly	Ellis Ex. 479, 2/10/03	DL-TX-0091098	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00102	03/??/1995	Reimbursement Comparison Worksheet	Marrs Ex. 44, 10/2/08	DL-TX-0076254	Expect	
00103	5/30/1995	Memo from Helen burnham re Albuterol WAC Pricing	Selenati Ex. 46, 5/4/05	DL-TX-0122497	Expect	
00104	5/3/1999	Memo from Todd Galles re Ippy Pricing	Bronstein Ex. 535, 3/11/03	n/a	Expect	
00105	1/24/1994	Ross Uhl Presentation Working A Home Care Pharmacy	Upp Ex. 498, 2/14/03	DL-TX-0075972	Expect	
00106	1/19/1995	Rick Upp Working Visit with	Gist Ex. 341, 11/5/02	DL-TX-0407112	Expect	
00107	1/21/1995	Rick Upp managers weekly recap	Tipton Ex. 500, 2/14/03	DL-TX-?	Expect	
00108	2/10/1995	Rick Upp Working Visit with	Tipton Ex. 502, 2/14/03	DL-TX-0407109	Expect	
00109	6/28/2000	Message from Russ Johnston to Rick Upp & Todd Galles	Galles Ex. 469, 2/6/03	DL-TX-0091434	Expect	
00110	9/28/1994	Memo from Robert Mozak re: Cromolyn Sales Update	Hill Ex. 8, 11/11/08	DL-TX-0161590	Expect	
00111	2/3/1995	Building on Success presentation	Hill Ex. 10, 11/11/08	DL-TX-0090875	Expect	
00112	2/3/1995	Answers for Presentation Albuterol	Hill Ex. 11, 11/11/08	DL-TX-0090878F	Expect	
00113	03/??/1995	Reimbursement Comparison Worksheet	Hill Ex. 12, 11/11/08	DEY-BO-0240246	Expect	
00114	TBD	Retail Questions	Hill Ex. 13, 11/11/08	DL-TX-0090869	Expect	
00115	4/5/1995	Memo from Todd Galles re Marketing update AWP Pricing & profit Gain	Hill Ex. 15, 11/11/08	DL-TX-0091109	Expect	
00116	5/7/1995	Literature Request Form	Hill Ex. 16, 11/11/08	DL-TX-0113662	Expect	
00117	02/??/1996	Dey Lab & Center Lab National Sales	Hill Ex. 18, 11/11/08	DL-TX-0088738	Expect	
00118	3/4/1996	Dey Albuterol Multidose Launch Manual	Hill Ex. 19, 11/11/08	DL-TX-0092785	Expect	
00119	1995	Weekly Sales Recap	Hill Ex. 20, 11/11/08	DEY-OIG-0125368	Expect	
00120	2/23/1994	Weekly Sales Recap	Hill Ex. 23, 11/11/08	DEY-OIG-0125361	Expect	
00121	01/??/1995	Account Call Report	Hill Ex. 24, 11/11/08	DL55741	Expect	
00122	5/5/2003	Federal Register, 68 FR 23731	Johnston Ex. 6, 12/10/08	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00123	7/20/1998	Letter from Gary Stone re Fully Executed Agreement	Johnston Ex. 7, 12/10/08	DL-TX-0006777	Expect	
00124	1/21/1999	Letter from Gary Stone re Contract Modification to Reduce Prices	Johnston Ex. 8, 12/10/08	DL-TX-0006765	Expect	
00125	5/27/1999	Letter from Jackie Perkins re Contract Modifications	Johnston Ex. 10, 12/10/08	DL-TX-0006752	Expect	
00126	8/11/1999	Letter from Jackie Perkins re Contract Modifications	Johnston Ex. 13, 12/10/08	DL-TX-0006738	Expect	
00127	11/23/1999	Letter from Jackie Perkins re Contract Modification	Johnston Ex. 14, 12/10/08	DL-TX-0006721	Expect	
00128	12/3/1999	Letter from Jackie Perkins re Contract Modification	Johnston Ex. 15, 12/10/08	DL-TX-0006716	Expect	
00129	2/23/2000	Purchase & Rebate Agreement between Dey LP & Anda, Inc.	Johnston Ex. 16, 12/10/08	DL-TX-0006606	May	
00130	3/3/2000	Letter from Russell Johnston re Contract Modification	Johnston Ex. 17, 12/10/08	DL-TX-0006712	Expect	
00131	12/??/1998	Letter from Gary Stone re Request for Quotation	Johnston Ex. 25, 12/10/08	DL-TX-0045757	Expect	
00132	4/17/2000	Letter from Russell Johnston re Price Adjustment on Short-Dated Product	Johnston Ex. 27, 12/10/08	DL-TX-0043531	Expect	
00133	8/11/1997	Letter from Cindy Daulong re Ipratropium Bromide Promotion	Johnston Ex. 29, 12/10/08	DL-TX-0027348	Expect	
00134	8/28/2002	Fax from Rosemary Logan re Cardinal Health Contract Listings of Awarded	Johnston Ex. 49, 12/11/08	DL-TX-0133467	May	
00135	8/10/1999	Ltr from Todd Galles re New 105-01 Albuterol Multidose Medicaid Ltrs	Johnston Ex. 53, 12/11/08	DL 63384	May	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00136	6/20/1996	Fax from Charles Rice Re Reduction in Generic Product Margins	Rice Ex. 580, 3/24/03	DL-TX-0162679	Expect	
00137	1/13/1997	Addition of Dey Ipratropium Bromide Inhalation Solution	n/a	DL-TX-0093127	Expect	
00138	7/23/1999	Memo from Debbie Bronstein & Todd Galles re: AWP	Bronstein Ex. 540, 3/11/03	DL-TX-0078198	May	
00139	1995	Memo from Bruce Tipton re: Robert	Marrs Ex. 46, 10/2/08	DEY-LABS-	Expect	
00140	11/3/1995	Memo from Bruce Tipton re: Managed Care Spec. (Nat'l Acct Manager NAM)	n/a	DEY-LABS-0282887	Expect	
00141	01/??/1996	Ross Uhl Sales Commission Worksheet	n/a	DEY-LABS-	Expect	
00142	10/9/1995	Memo from Bruce Tipton re Managed Care Spec. - Incentive Compensation	n/a	DEY-LABS-0282856	Expect	
00143	7/10/1995	Memo from Bruce Tipton Re: Managed Care Compensation	n/a	DEY-LABS-0282823	Expect	
00144	02/??/1995	"Building on Success," Memo from MozakR to Dey Sales and Marketing	Ricks Bey Ex. 7, 1/8/09	DL-TX-0096741	Expect	
00145	TBD	Albuterol Unit Dose Worksheet	Ricks Bey Ex. 9, 1/8/09	DL-TX-0090875	Expect	
00146	TBD	Retail Questions	Ricks Bey Ex. 11, 1/8/09	DL-TX-0090869	Expect	
00147	TBD	Reimbursement Comparison Worskheet	Ricks Bey Ex. 5, 1/8/09	DEY-BO-0240246	Expect	
00148	4/5/1995	Memo from Todd Galles re Marketing Update AWP Pricing & Profit Gain	Ricks Bey Ex. 12, 1/8/09	DL-TX-0091109	Expect	
00149	TBD	Michael Hannon Literature Request	Ricks Bey Ex. 13, 1/8/09	DL-TX-0113662	Expect	
00150	6/30/1994	Memo from Rick Upp re Work With	Ricks Bey Ex. 14, 1/8/09	DL-TX-0109420	Expect	
00151	1/1/1994	Robert Ellis Abridged Marketing Plan Cromolyn Sodium Nebulizer Solution	Ricks Bey Ex. 15, 1/8/09	DL-TX-0090967	Expect	
00152	12/15/1993	Cromolyn Sodium Nebulizer Solution Marketing Plan	Ricks Bey Ex. 16, 1/8/09	DL-TX-0091006	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00153	1994	Account Call Record	Ricks Bey Ex. 17, 1/8/09	DL-TX-0108725	Expect	
00154	3/18/1995	Weekly Sales Recap	Ricks Bey Ex. 18, 1/8/09	DL-TX-0114592	Expect	
00155	1994	Account Call Record	Ricks Bey Ex. 20, 1/8/09	DEY-OIG-0125324	Expect	
00156	1995	Account Call Report	Ricks Bey Ex. 21, 1/8/09	DL-TX-0113725	Expect	
00157	1/4/1996	Ltr from Todd Galles re pricing	n/a	DL-TX-0092589	Expect	
00158	5/6/1996	Ltr from Reuben Sandler re: First Databank System	n/a	DL-TX-0093200	Expect	
00159	2/11/1991	Ltr from Christine Nye re: Agreement	n/a	DL-TX-000914	Expect	
00160	5/31/2002	Memo from Mark Boudreau re MDI/WAC Adjustment	Johnston Ex. 51, 12/11/08	DL-TX-0163785	Expect	
00161	10/??/1995	Managed Care Western Region by Debi	n/a	DL-TX-0096611	Expect	
00162	1/13/1997	Memo from Todd Galles re: Ipratropium Bromide Inhalation Solution Haunch	n/a	DL-TX-0093102	Expect	
00163	5/8/1995	Memo from Robert Covay re: Achievement of Objectives for 1995	Marrs Ex. 874, 4/16/03	n/a	Expect	
00164	5/5/2000	Ltr from Thomas Bliley to Charles Rice	n/a	HHD135-1045	May	
00165	5/23/1995	1995 Compensation Criteria (Part B)	Marrs Ex. 873, 4/16/03		Expect	
00166	1/18/1996	Memo from Robert Mozak re New Product Supplemental Commissions	n/a	DEY-LABS-0281261	Expect	
00167	1/4/1996	Memo from Ross Uhl re Managed HealthCare Associates Promotion	n/a	DEY-BO-0240244	Expect	
00168	4/16/1996	Cheat sheet	n/a	DEY-BO-0272527	Expect	
00169	12/28/2002	First Databank Medicaid Coverage	n/a	DL58977	May	
00170	4/4/1996	Memo from Bruce Tipton re NAM's Part B Incentive Compensation	n/a	DEY-LABS-0281259	Expect	
00171	8/3/1995	Fax from Cindy Daulong re Reimbursement Comparison Worksheet	n/a	DEY-BO-0240245	Expect	

The United States' Exhibit List

Trial Exhibit #	Date of Document	Title or Brief Description	Depo Exhibit -deponent name, depo Ex. #, date of depo	Beginning Bates #	Intent to Offer	Objection
00172	3/31/2000	Ltr from Robert Mozak re Price Changes	n/a	EDEY-BO-	Expect	
00173	3/1/1996	Marketing Launch Plan, Albuterol Sulfate Inhalation Solution	n/a	DL-TX-0092055	Expect	
00174	3/1/1996	AWP Price List	n/a	DEY-BO-0272540	Expect	
00175	3/1/1995	Copy Clearance, Managed Care Inservice	n/a	DEY-BO-0239313	Expect	
00176	12/7/1998	Memo for Mike Meyer re: Cardinal Health Health GWSA	n/a	DL-BO-072295	Expect	
00177	07/??/00	Documents re OptiSource	Johnston Ex. 32, 12/11/08	DL-BO-157653	May	
00178	5/30/2001	Ltr from Martha McNeil re Medicaid Admin. Price Change	TX Ex. 0238	DL-0050063	May	
00179	9/11/1998	Redbook Product Listing Verification	Gmeiner Ex. 622, 1/30/03	DL-TX-001014	May	
00180	1/10/1997	Dey Lab Introduces Generic Ipratropium Bromide Inhalation Solution	n/a	DL-TX-0093562	May	
00181	1999	Albuterol products, picture	n/a	DL-BO-0254646	Expect	
00182	03/??/1999	Retail Reimbursement Comparison	n/a	DEY-BO-0258459	May	
00183	9/8/1995	Memo from Cindy Daulong re: Bid Reports July/Aug 1995 and Year-To-Date	Tipton Ex. 494, 2/13/03	DL-TX-0079904	May	
00184	12/29/1998	Ltr from Todd Galles re Dey WAC Price	n/a	DL-TX-0092435	May	
00185	5/30/1995	Pricing Update, fax to Beth Raider	n/a	FDB00918	May	
00186	6/20/2005	Ltr from Russell Johnston to Betty Reynolds re Modification to Agreement	n/a	DEY-LABS-0293726	May	
00187	04/??/1999	First Data Bank Technical Bulletin	Hirschmann Ex. 367, 11/12/02	R1-030088	May	
00188	5/30/1995	Fax from Dey Lab, re Price Alert & Pharmacy Blue Book Update	n/a	DL-006	May	
00189	4/27/1994	Cromolyn Sodium Pricing	n/a	DEY-BO-0272614	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00190	1995	Rick Upp Working Visit with	Gmeiner Ex. 630, 1/20/03	DL-TX-0407116	May	
00191	3/1/1996	Albuterol Sulfate Inhalation Solution,		DL-TX-0088914	Expect	
00192	3/22/2002	Memo from John Ditton re Ipra NS	n/a	EDEY-BO-	May	
00193	03/??/07	Ltr from Russell Johnston re Important New Product Announcement	n/a	HI-HI-000012936	May	
00194	7/29/1999	Memo from Juli Heath-Nevis re Contract Modification	n/a	DL-TX-0009658	May	
00195	11/??/03	Ltr from Russell Johnston re product packing enhancements	n/a	DEY-LABS-0292764	May	
00196	02/??/07	Ltr from Russell Johnston re Price	n/a	HI-HI-000012954	May	
00197	12/31/1997	Ltr from Eve Gmeiner re: Reducing WAC Pricing	Hirschmann Ex. 369, 11/12/02	FDB 000920	May	
00198	1/5/2000	Ltr from Steven Resnik re Lewin-Tag, Inc.	n/a	DEY-BO-0239157	May	
00199	7/26/2000	Memo from Susan Schrars re New Albuterol Inhalation and AWP/WAC	n/a	DL-TX-0093570	May	
00200	1999	Dey, Inc. Albuterol Dose Sales	n/a	DL 57093	May	
00201	9/1/1999	Warning Ltr from Norman Drezin re Ipratropium Bromide Inhalation Solution	n/a	n/a	May	
00202	TBD	Pricing Tutorial Terms	Rice Ex. 598, 3/24/03	DL-TX-0091086	May	
00203	1/2/1997	Dey Lab Monthly Pricing Summary	Marrs Ex. 875, 4/16/03		May	
00204	1/4/1999	Ltr from R F Mozak re State Medicaid	n/a	DL-TX-000991	May	
00205	12/17/1998	Ltr from Kathy Gutgesell re State Medicaid Agencies	n/a	DL-CA00063	May	
00206	3/12/2007	First DataBank Drug Pricing Policy	n/a	n/a	May	
00207	8/1/2006	Compliance Manual	n/a	DEY-LABS-	May	
00208	1/4/1999	Ltr from R F. Mozak re WAC price	Mozak Ex. 559, 3/13/03	DL-TX-000991	May	
00209	1/1/1999	Generic Wholesale Service Agreement	Erick Ex. 3, 6/17/08	CH0055539	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00210	10/7/1993	Fax from Rob Ellis re request for direct	Ellis Ex. 485, 2/10/03	FDB 000910	May	
00211	12/18/1996	Agreement re Profitability Enhancement	n/a	DL-TX-0004775	May	
00212	1/3/2003	Customer Profitability Analysis	n/a	DL-BO-159808	May	
00213	4/10/1995	Memo from Robb Ellis re Albuterol	n/a	DEY-BO-0240234	May	
00214	5/1/1994	Average Wholesale Price (AWP) List	n/a	DL-004	May	
00215	1/3/2003	Dey Customer Profitability Analysis	n/a	DL-TX-0161536	May	
00216	12/31/1997	Fax from Eve Fagrell Gmeiner re Dey Lab reducing WAC pricing	n/a	DL-TX-0093527	May	
00217	11/3/1998	Albuterol Unit Dose, Current Contract Price	Bronstein Ex. 544, 3/11/03	DL-TX-0092506	May	
00218	9/30/1994	Memo from Cindy Daulong re Cromolyn Price Rev. Retail/LTC Groups	Uhl Ex. 782, 2/24/03	DL-TX-0103583	May	
00219	3/2/1994	Gerimed History and Corporate Goals	n/a	TEV0106	May	
00220	6/7/1999	Ltr from Laura Sanchez re Cardinal Health ACCESS membership diskette	Erick Ex. 22, 6/27/08	DEY-BO-152856	May	
00221	1/13/1997	Ltr from Todd Galles re New Product Announcement Dey Ipratropium	n/a	DL-0050268	May	
00222	1/1/2005	Ltr from Russell Johnston re Pricing Database Admin.	n/a	DEY-LABS-0294389	May	
00223	07/??/1994	Sales Commentary by Charles Rice	Rice Ex. 348, 11/7/02	DL-TX-84812	Expect	
00224	1/29/1996	Memo from Mike Mike Hannum to Mary Anderle and others re 1996 National	n/a	DL-61217	May	
00225	2/18/1995	Weekly Sales Recap	n/a	DL-TX-0112380	Expect	
00226	5/30/1995	Memo Re Albuterol WAC Pricing	Gmeiner Ex. 628, 1/20/03	n/a	Expect	
00227	3/31/1998	Monthly Net Sales by Product	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00228	10/22/2000	Letter from Ropes & Gray with Supplemental Analysis of Why the United States Should Decline	n/a	n/a	Expect	
00229	6/27/2002	Presentation re Net Sales	n/a	DEY-BO-0031282	Expect	
00230	1/31/2003	Letter from Fleckman producing	n/a	n/a	Expect	
00231	5/15/2003	McKesson Customer Profitability by	n/a	n/a	Expect	
00232	10/23/2003	Ltr from David Adams re NMPI Pooling Rebate Agreement	Dey Ex. 096	DEY-LABS-0360178	Expect	
00233	8/18/2005	Dey's Responses and Objections to Subpoena Duces Tecum dated July 25,	n/a	n/a	Expect	
00234	TBD	Letters of Dey counsel producing documents to the State of Texas	n/a	n/a	Expect	
00235	1/27/1994	Key Accounting Visit	Uhl Ex. 784, 2/24/03	DL-TX-0109702	May	
00236	1/27/1994	Key Accounting Call	Uhl Ex. 783, 2/24/03	DL-TX-0109696	May	
00237	5/5/1995	Copy Clearance, 09-338-00, Albuterol Reimbursement Comparison Worksheet		DEY-BO-029300	May	
00238	10/9/1995	Albuterol Sales -- spreadsheet	Marrs Ex. 249, 5/2/03	DL-TX-0079286	May	
00239	3/8/1996	Gerimed Proposal	Uhl Ex. 785, 2/24/03	DL-TX-0021335	May	
00240	8/7/1997	Letter from Eve Fagrell-Gmeiner to Montcrieffe, Medical Data Institute.	Gmeiner Ex. 620, 1/20/03	DL-TX-001032	May	
00241	8/14/1997	Pricing Database Confirmation Form	Gmeiner Ex. 619, 1/20/03	DL-TX-001023	May	
00242	10/28/1997	Fax re: Dey Lab WP List	Gmeiner Ex. 621, 1/20/03	DL-TX-001037	May	
00243	3/6/1998	Gerimed Bid Package	Uhl Ex. 786, 2/24/03	DL-TX-020721	May	
00244	12/7/1998	Memo from Mike Meyer re Cardinal Health Health GWSA	n/a	DL-BO-072295	May	
00245	3/19/1999	Memo Re: Dey Combo	Uhl Ex. 781, 2/24/03	DL-TX-0091089	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00246	3/29/1999	09-0338-02, Copy Clearance, Albuterol Reimbursement Comparison Worksheet	n/a	DEY-BO-0239334	May	
00247	8/10/1999	Letter to State Medicaid Administrators	Galles Ex. 272, 3/1/06	DL-0050553	May	
00248	4/30/2000	Response to Document Requests Texas	Rice Ex. 70, 10/30/01	DL-TX-000908	May	
00249	1/3/2001	Memo re December 2000 Sales Reports	Mozak Ex. 240, 4/30/02	DL-TX-0078066	May	
00250	1/19/2001	Memo from Russell Johnston to all sales and marketing personnel	n/a	DEY-BO-0238116	May	
00251	6/24/1996	Ipratropium UDV Home Health Care Strategy Agenda	Tupa Ex. 641, 1/31/03	ROX-04997	Expect	
00252	TBD	Ipratropium Bromide UDV Launch Meeting Summary	Tupa Ex. 642, 1/31/03	ROX-04290	Expect	
00253	1/26/1996	January 26, 1996 Letter From Pope &	Pope Ex. 869, 4/14/03	ROX-04596	Expect	
00254	2/13/1996	February 13, 1996 Letter From Pope &	Pope Ex. 870, 4/14/03	ROX094588	Expect	
00255	2/23/1996	February 23, 1996 Letter From Pope &	Tupa Ex. 644, 1/31/03	ROX-04299	Expect	
00256	3/4/1996	March 4, 1996 Letter From Pope &	Tupa Ex. 645, 1/31/03	ROX-04301	Expect	
00257	4/9/1996	Fax Memo re: Product Launch	Tupa Ex. 648, 1/31/03	ROX-04606	Expect	
00258	8/25/1994	August 25, 1994 Employee Bulletin	Berkle Ex. 3, 10/31/08	RLI-AWP-	Expect	
00259	5/3/1996	May 3, 1996 Letter to Employees	Berkle Ex. 5, 10/31/08	RLI-AWP-	May	
00260	8/11/1995	Telefax re: UDV Strategy USA	Berkle Ex. 7, 10/31/08	RLI-AWP-	Expect	
00261	10/26/1995	Email re: UDV Strategy USA	Berkle Ex. 8, 10/31/08	TXEX00836	Expect	
00262	2/1/1996	Interoffice Memo re: Ipratropium UDV Meeting Review	Dusek Ex. 13, 11/13/09	RoxCA001987	Expect	
00263	1/24/1996	Ipratropium UDV Home Health Care Strategy Meeting Agenda	n/a	RLI-AWP-00300267	Expect	
00264	1996	Fax re: Ipratropium Bromide UDV Generic Launch Meeting Summary	Berkle Ex. 12, 10/31/08	RLI-AWP-00299557	Expect	
00265	1/26/1996	January 26, 1996 Letter from Pope &	Tupa Ex. 643, 1/31/03	ROX-04596	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00266	4/17/1996	Ipratropium Inhalation Solution UDV Marketing Plan	Via Ex. 7, 10/18/05	RoxCT00060403	Expect	
00267	4/28/1996	IBUDV Pricing Strategy for Legal Review	Via Ex. 8, 10/18/05	ROXCA001981	Expect	
00268	10/11/1996	Interoffice Memo re: Metaproterenol	n/a	RLI-AWP-	May	
00269	4/22/1996	New From Roxane Laboratories: Ipratropium Inhalation Solution UDV	n/a	RLI-AWP-00430904	Expect	
00270	2/16/1996	New From Roxane Laboratories: Azathioprine 50 mg Scored Tablets	Dusek Ex. 17, 11/13/09	RLI-AWP-00077298	Expect	
00271	11/17/1995	Hydroxyurea Capsules USP 500 mg	n/a	RLI-AWP-	May	
00272	05/??/1996	Now Available From Roxane Laboratories: Ipratropium Bromide	n/a	RLI-AWP-00068016	Expect	
00273	1996	Edward Tupa 1996 Performance	Tupa Ex. 650, 1/31/03	ROX-TX-02169	May	
00274	TBD	Ipratropium Bromide Price Reduction	n/a	RLI-AWP-	Expect	
00275	10/2/1998	Email re: Bll Gmbh enquiry into Ipratropium Bromide Pricing	Waterer Ex. 51, 10/25/01	ROX-6062	Expect	
00276	3/30/1995	Marketing Memo # 12 re: Oramorph Price Increase	Shaffer Ex. 7, 5/21/08	RLI-AWP-00171001	Expect	
00277	1/31/1997	Marketing Memo #1 re: Price Change for Oramorph SR and MSContin	Shaffer Ex. 8, 5/21/08	RLI-AWP-00164037	Expect	
00278	2/7/1998	Memo re: WAC Adjustment Implementation Update	Tupa Ex. 652, 1/31/03	ROX-TX-01264	Expect	
00279	12/8/1997	Email re: Pricing Books	Mayhew Ex.34, 11/9/04	ROX-TX-00839	Expect	
00280	11/5/1999	Email re: Florida Medicaid	Mayhew Ex.37, 11/9/04	ROX-TX-00840	Expect	
00281	9/3/1997	Email re: Pricing - Meperidine, Ipratropium, and Thioridazine Intensol	Paoletti Ex. 43, 11/9/04	ROX-05632	Expect	
00282	5/10/1994	Interoffice Memo re: Ipratropium Bromide	Feldman Ex. 252, 6/25/2002	ROX-03792	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00283	7/6/2000	Trade Relations Structure	Kutner Ex. 1, 12/9/08	RLI-AWP-	Expect	
00284	3/31/1997	Marketing Memo # 7 re: Duraclon Medicaid Reimbursement	Shaffer Ex. 4, 5/21/08	RLI-AWP-00170424	May	
00285	3/31/1997	Marketing Memo # 8 re: Duraclon Medicaid Reimbursement	Shaffer Ex. 5, 5/21/08	RLI-AWP-00170426	May	
00286	7/18/1997	Marketing Memo # 11 re: Duraclon reimbursement information	Shaffer Ex. 6, 5/21/08	RLI-AWP-00170434	May	
00287	7/20/2000	Email re: Kaiser -- CCP	Via Ex. 12, 10/18/05	RoxCT0050830	Expect	
00288	TBD	Price Comparison -- Oramorph SR vs. MS	Shaffer Ex. 15, 5/21/08	RLI-AWP-	Expect	
00289	TBD	Price Comparison -- Oramorph SR vs.	Shaffer Ex. 16, 5/21/08	RLI-AWP-	Expect	
00290	4/26/2000	Email re: Bergen CPS Long Term Care Pricing 4-24-00	Shaffer Ex. 13, 5/21/08	RLI-AWP-00170506	Expect	
00291	3/15/1999	Email re: PBI Contract Pricing Oramorph SR vs. MS Contin	Shaffer Ex. 17, 5/21/08	RLI-AWP-00321555	Expect	
00292	3/28/2000	Email re: Revised SWOT Analysis	Shaffer Ex. 18, 5/21/08	SHAFFER001438	Expect	
00293	11/2/1999	Oramorph SR 2000 Marketing Plan	Shaffer Ex. 19, 5/21/08	RLI-AWP-	May	
00294	1/11/1999	Memo re Oramorph SR Price Increase	Shaffer Ex. 10, 5/21/08	RLI-AWP-	Expect	
00295	12/??/1998	National Accounts Monthly Report December 1998	Russillo Ex. 18, 1/8/09	BOEH01046914	Expect	
00296	08/??/1998	National Accounts Monthly Report,	n/a	BOEH00138145	Expect	
00297	05/??/1999	Letter re: Novation LLC Agreement	n/a	BOEH01227177	Expect	
00298	TBD	Novation Pharmacy Purchasing Program, Invitation to Bid	n/a	BOEH04393944	Expect	
00299	9/30/1999	Email re: RLI Action Steps	Via Ex. 14, 10/18/05	RoxCA001847	Expect	
00300	05/??/1999	Letter re: Novation LLC Agreement	n/a	RLI-AWP-	Expect	
00301	1/7/1999	Email re: NovaPlus ipratropium bromide	n/a	RLI-AWP-	Expect	
00302	3/28/2000	Email re: Ipratropium prices	n/a	RLI-AWP-	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00303	TBD	Novation LLC Phase 3 Request for Pricing Quotations	n/a	RLI-AWP-00127471	Expect	
00304	5/20/1998	Memorandum re: Novation Proposal	n/a	RLI-AWP-	Expect	
00305	9/19/2000	Letter from John Powers to Novation re Ipratropium	n/a	RLI-AWP-00213199	Expect	
00306	1/15/2001	Email re: Novation Sole Source/No Bid	n/a	RLI-AWP-	Expect	
00307	6/1/1999	New Product Information, ipratropium bromide (NovaPlus)	n/a	RLI-AWP-00425586	Expect	
00308	9/13/2000	Email re: NovaPlus Meeting	n/a	RLI-AWP-	Expect	
00309	07/??/1999	Price Adjustment Request re:	Kutner Ex. 4, 12/9/08	RLI-AWP-	Expect	
00310	7/21/1999	Ipratropium Bromide Price Reduction	Kutner Ex. 5, 12/9/08	RLI-AWP-	Expect	
00311	09/??/1999	Price Adjustment Request, Ipratropium	Kutner Ex. 6, 12/9/08	RLI-AWP-	Expect	
00312	9/15/1999	Ipratropium Bromide Price Reduction	Kutner Ex. 7, 12/9/08	RLI-AWP-	Expect	
00313	4/20/2000	Azathioprine/Ipratropium Bromide Price Reduction Letter	Kutner Ex. 8, 12/9/08	RLI-AWP-00212132	Expect	
00314	4/17/2000	Price Adjustment Request Ipratropium	Kutner Ex. 9, 12/9/08	RLI-AWP-	Expect	
00315	TBD	SWOT National Accounts	Kutner Ex. 10, 12/9/08	RLI-AWP-	Expect	
00316	8/11/1999	Price Adjustment Request, Azathioprine	Kutner Ex. 11, 12/9/08	RLI-AWP-	Expect	
00317	8/12/1999	Azathioprine Price Reduction Letter	Kutner Ex. 12, 12/9/08	RLL-AWP-	Expect	
00318	8/5/1999	Email re: Geneva Azathioprine	Kutner Ex. 13, 12/9/08	RLI-AWP-	Expect	
00319	9/10/1999	Email re: Azathioprine AWP	Kutner Ex. 14, 12/9/08	RLI-AWP-	Expect	
00320	9/10/1999	Price Adjustment Request, Azathioprine	Kutner Ex. 15, 12/9/08	RLI-AWP-	Expect	
00321	TBD	Price Reduction Letter, Azathioprine	Kutner Ex. 16, 12/9/08	RLI-AWP-	Expect	
00322	1/28/1999	January 28, 1999 News Release	Russillo Ex. 2, 1/8/09	BICJURIS 0037	Expect	
00323	1999	Roxane Laboratories 1999	Russillo Ex. 4, 1/8/09	ROX-01438	Expect	
00324	9/22/2000	Email re: !Reorg_PAC_2.ppt; 091800 minutes final.doc	Russillo Ex. 12, 1/8/09	BOEH01311854	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00325	9/10/1999	Telefax re: Azathioprine Price Analysis	Russillo Ex. 20, 1/8/09	RLI-AWP-	Expect	
00326	9/10/1999	Email re: Azathioprine AWP	Russillo Ex. 21, 1/8/09	RLI-AWP-	Expect	
00327	7/5/2000	Email re: CVS Furosemide Opportunity	Russillo Ex. 24, 1/8/09	RLI-AWP-	Expect	
00328	7/7/2000	Email re: Cardinal Counter & Furosemide	Russillo Ex. 25, 1/8/09	RLI-AWP-	Expect	
00329	7/7/2000	Email re: Cardinal Counter & Furosemide	Russillo Ex. 26, 1/8/09	RoxCT0049701	Expect	
00330	7/26/2000	Email re: Furosemide Tablet AWP	Russillo Ex. 27, 1/8/09	RoxCT0051341	Expect	
00331	10/27/1999	Email re: Pred Price Impact Analysis	Russillo Ex. 23, 1/8/09	BOEH01650840	Expect	
00332	10/23/1998	October 23, 1998 Employee Bullentin	Berkle Ex. 27, 10/31/08	RLI-AWP-	Expect	
00333	1999	1999 Roxane Laboratories	Sykora Ex. 15, 12/4/08	BOEH02582439	Expect	
00334	TBD	Azathioprine Price Reduction Letters	n/a	RLI-AWP-	Expect	
00335	4/18/2000	Email re: Furosemide AWP	Paoletti Ex. 56, 11/10/04	PAOLETTI01846	Expect	
00336	5/2/2000	Email re: Furosemide AWP	Paoletti Ex. 57, 11/10/04	PAOLETTI01844	Expect	
00337	5/3/2000	Email re: Furosemide AWP	Gordon Ex. 6, 11/4/05	RoxCT0051120	Expect	
00338	4/17/2000	Email re: Furosemide AWP	Paoletti Ex. 9, 11-30-05	ROXCT0051213	Expect	
00339	4/18/2000	Email re: Furosemide AWP	Sykora Ex. 2, 11/2/05	RoxCT0049706	Expect	
00340	7/5/2000	Email re: CVS Furosemide Opportunity	Sykora Ex. 4, 12/4/08	RLI-AWP-	Expect	
00341	7/7/2000	Email re: Cardinal Counter & Furosemide	Sykora Ex. 6, 12/4/08	RLI-AWP-	Expect	
00342	7/7/2000	Email re: Cardinal Counter & Furosemide	Sykora Ex. 7, 12/4/08	PAOLETTI01841	Expect	
00343	7/26/2000	Email re: Furosemide Tablet AWP	Sykora Ex. 8, 12/4/08	RLI-AWP-	Expect	
00344	7/26/2000	Email re: Furosemide Tablet AWP	Sykora Ex. 9, 12/4/08	RLI-AWP-	Expect	
00345	8/2/2000	Email re: Furosemide Price Changes	Sykora Ex. 10, 12/4/08	PAOLETTI01933	Expect	
00346	8/8/2000	Email re: Furosemide Price Changes	Sykora Ex. 11, 12/4/08	RLI-AWP-	Expect	
00347	8/15/2000	Email re: RLI Price Change Furosemide -	Sykora Ex. 5, 11/2/05	ROXCT0051141	Expect	
00348	8/10/2000	Email re: Furosemide Price Changes	Sykora Ex. 4, 11/2/05	RoxCT0051147	Expect	
00349	08/??/00	National Accounts Monthly Report	n/a	BOEH02708378	Expect	
00350	4/14/2000	Email re: Medicare Reimbursement	Feldman Ex. 94, 11/17/04	PAOLETTI17638	Expect	
00351	TBD	Roxicodone Distribution Workshop	Shaffer Ex. 29, 8/5/08	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00352	7/26/2000	Memo re: 3rd Trimester Palliative Care Sales Meeting	Sykora Ex. 12, 12/4/08	RLI-TX-63141	Expect	
00353	1999	Distribution Workshop	n/a	BOEH01301724	Expect	
00354	TBD	Memo re: Training manual - Roxicodone	n/a	RLI-AWP-	Expect	
00355	9/8/2000	Reimbursement Background	Shaffer Ex. 22, 5/21/08	RLI-AWP-	Expect	
00356	TBD	Roxicodone 15mg/30mg Tablet Launch	Shaffer Ex. 21, 5/21/08	RLI-AWP-	Expect	
00357	2000	New Product Introduction -- Roxicodone	Shaffer Ex. 30, 8/5/08	RLI-AWP-	Expect	
00358	TBD	Curriculum Vitae W. Fred Duy	Duy Ex. 2, 12/16/08	RLI-AWP-	Expect	
00359	TBD	Corporate Data Sheet, Roxane	Duy Ex. 4, 12/16/08	RLI-AWP-	Expect	
00360	TBD	Inter-company Memo re: Medicaid Classification of Purdue Frederick MS	Duy Ex. 14, 12/16/08	BOEH02583593	Expect	
00361	3/31/1997	Marketing Memo # 8 re: Duraclon	Duy Ex. 18, 12/16/08	BOEH01986238	May	
00362	9/29/1998	Email re: Albuterol Medicaid Reimbursement Reduction	Duy Ex. 20, 12/16/08	RLI-AWP-00387380	Expect	
00363	5/10/1994	Interoffice Memo re: lpratropium	Duy Ex. 22, 12/16/08	RLI-AWP-	Expect	
00364	TBD	Palliative Care Field Force	Duy Ex. 23, 12/16/08	BOEH01345943	Expect	
00365	1/31/1997	Marketing Memo # 1 re: Price Change for Oramorph SR and MS Contin	Duy Ex. 24, 12/16/08	RLI-AWP-00164037	Expect	
00366	3/30/1995	Marketing Memo # 12 re: Price Increase	Duy Ex. 25, 12/16/08	BOEH01149992	Expect	
00367	8/12/2000	Email re: Roxicodone 15/30 mg Launch	Duy Ex. 33, 12/16/08	SHAFFER001451	Expect	
00368	8/12/2000	Email re: Roxicodone 15/30 mg Launch	Duy Ex. 34, 12/16/08	Shaffer001451	Expect	
00369	8/12/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 35, 12/16/08	BOEH00236146	Expect	
00370	8/14/2000	Email re: Roxicodone Pricing Proposal	Duy Ex. 36, 12/16/08	BOEH00236390	Expect	
00371	8/15/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 37, 12/16/08	BOEH00236367	Expect	
00372	8/18/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 39, 12/16/08	BOEH00236090	Expect	
00373	8/14/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 40, 12/16/08	BOEH00236135	Expect	
00374	8/14/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 41, 12/16/08	BOEH00236074	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00375	9/8/2000	Email re: Market Overview Slides	Duy Ex. 46, 2/16/08	BOEH01301774	Expect	
00376	10/28/1998	October 28, 1998 Minutes of the Meetings of the Board of Directors Boehringer Ingelheim Corporation	Berkle Ex. 4, 10/31/08	BICJURIS0228	Expect	
00377	1/26/1996	January 26, 1996 Letter from Pope &	Berkle Ex. 13, 10/31/08	RLI-AWP-	Expect	
00378	5/17/1996	Email re: Atrovent (I.B.) Solution	Berkle Ex. 15, 10/31/08	RLI-AWP-	Expect	
00379	10/20/1996	Interoffice Memo re: Ipratropium Bromide Back Order	Berkle Ex. 17, 10/31/08	RLI-AWP-00431168	May	
00380	1996	Why Stay With Ipratropium Bromide?	Berkle Ex. 18, 10/31/08	RLI-AWP-	May	
00381	2/27/1998	Interoffice Memo re: Premier	Berkle Ex. 23, 10/31/08	RLI-AWP-	May	
00382	6/12/1998	Interoffice Memo re: Premier	Berkle Ex. 24, 10/31/08	RLI-AWP-	May	
00383	1998	Roxane Commitment Agreement	Berkle Ex. 25, 10/31/08	RLI-AWP-	Expect	
00384	2001	Email re: Pricing Policy and Procedure -	Berkle Ex. 31, 10/31/08	RLI-AWP-	Expect	
00385	8/12/2000	Email re: Roxicodone 15/30 mg. Launch	Berkle Ex. 34, 10/31/08	Shaffer001451	Expect	
00386	8/22/2000	Interoffice Memo re: Recommend Pricing Roxicodone IR 15 & 30 mg	Berkle Ex. 35, 10/31/08	BOEH00242612	Expect	
00387	1/28/1999	January 28, 1999 News Release	Berkle Ex. 149, 1/27/05	BICJURIS0037	Expect	
00388	10/20/1997	Email re: BUOC	Berkle Ex. 150, 1/27/05	ROX-5980	May	
00389	10/26/1995	Email re: UDV Strategy USA	Berkle Ex. 152, 1/27/05	ROX-04860	Expect	
00390	6/6/2000	Email re: Combivent UDV Spreadsheet	Berkle Ex. 157, 1/27/05	ROX-TX-16255	Expect	
00391	9/9/1997	Fax re: Ranitidine Proposal	Carr-Hall Ex. 5, 12/12/2008	BOEH00144415	May	
00392	10/14/1997	Email re: Competitor Information Bergen Roxicet	Carr-Hall Ex. 7, 12/12/2008	RLI-AWP-00327293	Expect	
00393	07/??/1999	National Accounts Monthly Report July 1999	Carr-Hall Ex. 9, 12/12/2008	BOEH01051925	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00394	5/4/2000	Email re: CCP Contract Price AWP Spread	Carr-Hall Ex. 10, 12/12/2008	RLI-AWP-00004097	May	
00395	TBD	Bergen Brunswick Oramorph Message to Good Neighbor Pharmacies	Carr-Hall Ex. 11, 12/12/2008	RLI-AWP-00164990	Expect	
00396	3/30/1998	Email re: Monthly Reports	Carr-Hall Ex. 14, 12/12/2008	BOEH01046749	Expect	
00397	05/??/1998	National Accounts Monthly Reports May 1998	Carr-Hall Ex. 16, 12/12/2008	RLI-AWP-00327751	Expect	
00398	06/??/1998	National Accounts Monthly Reports June 1998	Carr-Hall Ex. 17, 12/12/2008	BOEH01046677	Expect	
00399	3/20/2000	Interoffice Memo re: March Palliative Care Report	Carr-Hall Ex. 19, 12/12/2008	BOEH02536323	Expect	
00400	04/??/00	Colin Carr-Hall Monthly Report April 2000	Carr-Hall Ex. 20, 12/12/2008	BOEH01051884	Expect	
00401	TBD	Furosemide AWP	Carr-Hall Ex. 22, 12/12/2008	RLI-AWP-00330803	Expect	
00402	8/10/2000	Email re: Furosemide Price Changes Approved	Carr-Hall Ex. 23, 12/12/2008	RLI-AWP-00410248	Expect	
00403	12/??/1998	National Accounts Monthly Report December 1998	Carr-Hall Ex. 26, 12/12/2008	BOEH01046832	Expect	
00404	8/5/1999	Email re: Geneva Azathioprine Competitive Info	Carr-Hall Ex. 28, 12/12/2008	RLI-AWP-00361425	Expect	
00405	9/12/1999	Email re: Azathioprine AWP	Carr-Hall Ex. 29, 12/12/2008	BOEH02612352	Expect	
00406	9/13/1999	Letter re: Product Price Change Notification	Carr-Hall Ex. 30, 12/12/2008	BOEH02613711	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00407	07/??/1998	National Accounts Monthly Report July 1998	Carr-Hall Ex. 32, 12/12/2008	BOEH01052932	Expect	
00408	11/3/1997	Email re: Oct. 29 Visit/Meetings	Carr-Hall Ex. 33, 12/12/2008	RLI-AWP-00248880	Expect	
00409	5/29/1999	Email re: Barnes Wholesaler Update	Carr-Hall Ex. 35, 12/12/2008	RLI-AWP-00182686	May	
00410	6/6/1999	Email re: NovaPlus IBUDV Orders	Carr-Hall Ex. 36, 12/12/2008	BOEH00892644	Expect	
00411	8/25/1999	CPS Super Bid RFP Q and A sheet	Carr-Hall Ex. 38, 12/12/2008	BOEH01046410	Expect	
00412	TBD	Dey Recognize the Difference	Carr-Hall Ex. 40, 12/12/2008	BOEH01050028	Expect	
00413	5/11/1998	Price Adjustment Request, Ipratropium Bromide	Carr-Hall Ex. 41, 12/12/2008	RLI-AWP-00252141	Expect	
00414	9/29/1999	Email re: Insource Baseline Rebate Retro to Jan 1st	Carr-Hall Ex. 42, 12/12/2008	RLI-AWP-00080839	Expect	
00415	6/3/1996	Fax re: Addition of Ipratropium Bromide Inhalation Solution	Trowbridge Ex. 56, 10/25/01	n/a	May	
00416	TBD	Dusek Resume	Dusek Ex. 2, 11/13/09	n/a	May	
00417	9/8/1995	Email re: Azathioprine	Dusek Ex. 5, 11/13/09	RLI-AWP-	Expect	
00418	12/19/1995	Interoffice Memo re: AWP Updates for	Dusek Ex. 9, 11/13/09	RLI-AWP-	Expect	
00419	1996	Sales Strategy	Dusek Ex. 11, 11/13/09	RLI-AWP-	Expect	
00420	TBD	Azathioprine slideshow	Dusek Ex. 12, 11/13/09	RLI-AWP-	Expect	
00421	2/19/1996	Marketing Memo #4 re: Azathioprine	Dusek Ex. 19, 11/13/09	RLI-AWP-	Expect	
00422	3/4/1996	Letter re: application for inclusion of Azathioprine on Texas Vendor Drug	Dusek Ex. 21, 11/13/09	RLI-AWP-00078343	Expect	
00423	12/31/1998	Dawn Gordon 1998 Performance	Gordon Ex. 127, 1/25/05	GORDON 0076	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00424	TBD	Dawn Gordon 2000 Performance	Gordon Ex. 128, 1/25/05	GORDON 0042	Expect	
00425	4/11/2000	Email re: Combivent UDV	Gordon Ex. 129, e/25/05	ROX-TX-16239	May	
00426	TBD	Distribution Workshop Slideshow	Paoletti Ex. 65, 11/10/04	PAOLETTI20637	Expect	
00427	5/3/2000	Email re: Furosemide	Paoletti Ex. 58, 11/10/04	PAOLETTI01843	Expect	
00428	5/3/2000	Email re: CCP Issues	Gordon Ex. 136, 1/25/05	PAOLETTI01213	May	
00429	TBD	Distribution Workshop Slideshow	Gordon Ex. 3, 11/4/05	PAOLETTI20637	Expect	
00430	5/3/2000	Email re: Furosemide	Gordon Ex. 6, 11/4/05	RoxCT0051120	Expect	
00431	07/??/1999	National Accounts Monthly Report July	Gordon Ex. 7, 11/4/05	ROX-CA 002265	Expect	
00432	8/19/1999	Price Reduction Letters	Gordon Ex. 9, 11/4/05	ROX-TX-07265	Expect	
00433	TBD	Mark Shaffer Resume	Shaffer Ex. 1, 5/21/08	n/a	Expect	
00434	4/19/2004	Slideshow re: Legal Entity Project	Tetzner Ex. 1, 10/19/04	BICJURIS1066	Expect	
00435	4/19/2004	Minutes of the Joint Meeting of the Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharmaceuticals,	Tetzner Ex. 3, 10/19/04	BICJURIS0889	Expect	
00436	TBD	Boehringer Ingelheim Corporation -- 2003 Consolidated Statement of Income	Tetzner Ex. 12, 10/19/04	BICJURIS0910	Expect	
00437	2003	Roxane Laboratories Inc. -- Statement of Income 2003	Tetzner, Ex. 13, 10/19/04	BICJURIS0919	Expect	
00438	TBD	Consolidated Net Cash Position, BIC and	Tetzner Ex. 19, 10/19/04	BICJURIS1124	Expect	
00439	TBD	Palliative Care Field Force	Shaffer Ex. 12, 5/21/08	RLI-AWP-	May	
00440	3/6/1998	Request for GeriMed Proposal	Feldman Ex. 251, 6/25/02	ROX-TX-04056	Expect	
00441	3/3/1998	InterOffice Memo re: WAC Change	Paoletti Ex. 46, 11/9/04	ROX-03041	Expect	
00442	6/29/2000	Email re: CVS Furosemide Opportunity	Feldman Ex. 91, 11/17/04	PAOLETTI01907	Expect	
00443	7/7/2000	Email re: Cardinal Counter & Furosemide	Paoletti Ex. 63, 11/10/04	PAOLETTI01841	Expect	
00444	TBD	Email re: Furosemide Price Changes-	Russillo Ex. 28, 1/8/09	PAOLETTI01933	Expect	
00445	1999	1999 Roxane Laboratories	King Ex. 101, 12/1/04	ROX-01438	Expect	
00446	10/20/1997	Email re: BUOC	King Ex. 104, 12/1/04	ROX-5980	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00447	10/23/1996	InterOffice Memo re: Atrovent Solution	King Ex. 109, 12/1/04	ROX-TX-00707	May	
00448	7/24/2000	Email re: Furosemide	Paoletti Ex. 62, 11/10/04	PAOLETTI01840	Expect	
00449	7/31/1987	Federal Register, Volume 52, Part 447	Waterer Ex. 2, 12/12/08	n/a	Expect	
00450	9/29/1998	Judy Waterer -- September 1999 Monthly Report -- Multisource Products	Paoletti Ex. 42, 11/9/04	ROX-TX-15106	Expect	
00451	3/13/1998	March 13, 1998 Letter Re: WAC/AWP	Mayhew Ex. 33, 11/9/04	ROX-TX-14599	Expect	
00452	??/??/1999	1999 Roxane Organizational Chart	Waterer Ex. 46, 10/25/01	ROX-01438	Expect	
00453	3/3/1998	Interoffice Memo re: WAC Change	Waterer Ex. 50, 10/25/01	ROX-05786	Expect	
00454	12/31/2000	James Rowenhorst 2000 Performance	Ciarelli Ex. 259, 6/26/02	ROX-TX02989	May	
00455	6/6/2000	Email re: Combivent UDV SpreadSheet	Rowenhorst Ex. 861, 4/3/03	ROX-TX-16255	May	
00456	TBD	Home Health Reimbursement Slideshow	Rowenhorst Ex. 867, 4/3/03	ROX-TX-16273	May	
00457	1998	Price List	Mayhew Ex.29, 11/9/04	ROX-TX-14702	Expect	
00458	8/19/1998	Gold Sheet -- Hydromorphone	Mayhew Ex. 31, 11/9/04	PAOLETTI09035	Expect	
00459	4/19/2004	Legal Entity Project	McIntyre Ex. 2, 2/26/09	BICJURIS1066	Expect	
00460	1996	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 15, 2/26/09	BOEH04600197	Expect	
00461	1997	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 16, 2/26/09	BOEH04600254	Expect	
00462	1998	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 17, 2/26/09	BOEH04600302	Expect	
00463	2001	Roxane Laboratories -- Unanimous Written Consent, approving year-end 2000 and 2001 Financials	McIntyre Ex. 20, 2/26/09	BOEH04600392	Expect	
00464	2002	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 22, 2/26/09	BOEH04600430	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00465	2003	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 23, 2/26/09	BOEH04600465	Expect	
00466	2007	Roxane Laboratories -- Unanimous Written Consent, approving year-end	McIntyre Ex. 24, 2/26/09	BOEH04600092	Expect	
00467	7/24/2000	Email re: Furosemide	Tavolaro Ex. 4, 11/22/05	RoxCT0049700	Expect	
00468	7/26/2000	Email re: Furosemide Tablet AWP	Tavolaro Ex. 5, 11/2/05	RoxCT0051341	Expect	
00469	4/19/2000	Furosemide Pricing Proposal	Tavolaro Ex. 8, 11/2/05	RoxCT0049712	Expect	
00470	TBD	Leslie Paoletti Resume	Paoletti Ex. 38, 11/9/04	ROX-TX-14104	May	
00471	12/19/1997	Email re: Source Rebate Changes Effective 12/1/97	Paoletti Ex. 39, 11/9/04	PAOLETTI03396	Expect	
00472	10/20/1999	Letter re: Product Listing For Roxane	Paoletti Ex.45, 11/9/04	ROX-TX-00859	Expect	
00473	6/24/1998	Email re: RITE-AID Hydroxyurea POA	Paoletti Ex.49, 11/9/04	PAOLETTI04184	May	
00474	1/14/1999	Email re: Pred 2.5 mg	Paoletti Ex. 50, 11/9/04	PAOLETTI06374	May	
00475	9/29/1998	Email re: Albulerol Medicaid Reimbursement Reduction	Paoletti Ex. 51, 11/9/04	D0000102	May	
00476	7/25/2000	Email re: Furosemide Table AWP	Paoletti Ex. 60, 11/10/04	PAOLETTI 01901	Expect	
00477	TBD	Furosemide AWP	Paoletti Ex. 61, 11/10/04	PAOLETTI 01830	Expect	
00478	1/10/2000	Email re: Price Change Procedures	Marsh Ex. 164, 3/2/05	RLI-TX-13852	May	
00479	5/31/2001	Email re: Sales Catalog Issues	Paoletti Ex. 176, 3/8/05	PAOLETTI 67995	May	
00480	8/21/2000	Email re Business Requirements - Sales	Marsh Ex. 162, 3/2/05	BOEH00598286	Expect	
00481	7/14/1997	Letter re: Roxane Laboratories Wholesale Source Partners Program	Brunk Ex. 26, 11/4/04	TXEX00135	May	
00482	3/13/1998	Email re: WAC Adjustment	Paoletti Ex. 2, 11/30/05	ROXMA007932	Expect	
00483	11/16/1998	Email re: Source Price Grid	Paoletti Ex. 3, 11/30/05	RoxCT0051571	Expect	
00484	11/5/1999	Email re: Florida Medicaid	Paoletti Ex. 5, 11/30/05	RoxCT0059902	Expect	
00485	7/25/2000	Email re: Furosemide Tablet AWP	Paoletti Ex. 10, 11/30/05	RoxCT0051127	Expect	
00486	7/26/2000	Email re: Furosemide Tablet AWP	Paoletti Ex. 11, 11/30/05	RoxCT0051341	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00487	8/10/2000	Email re: Furosemide AWP Change Notification/NAMs Letter of Approval	Paoletti Ex. 12, 11-30-05	RoxCT0051151	Expect	
00488	8/2/2000	Email re: Standby Statement Furosemide Price Change	Paoletti Ex. 13, 11-30-05	RoxCT0051156	Expect	
00489	TBD	Email re: Furosemide price change Infor for Gerstenberg	Paoletti Ex. 14, 11-30-05	RoxCT0051162	Expect	
00490	9/10/1995	Email re: Azathioprine	Dusek Ex. 6, 11/13/09	RLI-AWP-	Expect	
00491	4/7/1997	Email re: RLI's Future Status	n/a	BOEH04353260	Expect	
00492	3/31/1999	Email re: Lithium	Russillo Ex. 13, 1/8/09	BOEH00223891	Expect	
00493	3/31/1999	Email re: Azathioprine Price Change	n/a	BOEH01648789	Expect	
00494	5/31/2001	Email re: For Judy	n/a	BOEH01612209	May	
00495	8/22/2000	Email re: Roxicodone	Duy Ex. 43, 12/16/08	BOEH00235951	Expect	
00496	1999	Unanimous Written Consent, April 30, 1999 Dividend	McIntyre Ex. 18, 2/26/09	BOEH04600292	Expect	
00497	3/28/1996	Fax Memorandum re: Home Care Hit List	Tupa Ex. 646, 1/31/03	ROX-00734	Expect	
00498	5/21/1996	Interoffice Memo re: Meeting with Representatives from Dey Laboratories	Tupa Ex. 649, 1/31/03	ROX-04401	May	
00499	10/13/2004	October 13, 2004 Employee Bulletin	n/a	RLI-AWP-	May	
00500	8/20/1999	Letter re: Response to Request for Pricing Information	Russillo Ex. 5, 1/8/09		Expect	
00501	11/??/02	Unanimous Written Consent, November 26, 2002 Dividend	McIntyre Ex. 21, 2/26/09	BOEH02708378	Expect	
00502	3/24/2000	Email re: Cromolyn Pricing File	n/a	BOEH01652539	May	
00503	TBD	Capitalization Chart	n/a	Capitalization	Expect	
00504	9/8/1999	Email re: Azathioprine/Alprazolam Pricing Approvals	Russillo Ex. 22, 1/8/09	RLI-AWP-00113233	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00505	5/30/2000	Unanimous Written Consent, May 30, 2000 Dividend	McIntyre Ex. 19, 2/26/09	BOEH04600326	Expect	
00506	10/1/1999	Boehringer Board Minutes	n/a	BICJURIS0190	Expect	
00507	8/3/1998	Hydromorphone HCl Increase Proposal	n/a	RLI-AWP-	Expect	
00508	7/29/1998	Judy Waterer -- July 1998 Monthly	Waterer Ex. 6, 11/29/05	RoxCT0070004	Expect	
00509	4/1/1999	Roxane Customer Agreement	Sykora Ex. 17, 12/4/08	RLI-AWP-	Expect	
00510	8/17/2000	Email re: Roxicodone 15/30 mg. Launch	Duy Ex. 38, 12/16/08	BOEH00236145	Expect	
00511	12/12/1996	Email re: lpratropium Bromide UDV	n/a	RLI-AWP-	May	
00512	9/19/2000	Price Reduction Letter, NovaPlus lpratropium Bromide	n/a	RLI-AWP-00148162	Expect	
00513	11/25/1996	InterOffice Memo re: Azathioprine Price Increase Analysis	Dusek Ex. 25, 11/13/09	RLI-AWP-00077295	May	
00514	2/20/1999	Email Re: RLI 0299 Prelu-2 Increase	Russillo Ex. 8, 1/8/09	BOEH01311260	Expect	
00515	3/7/2000	Email re: AWP	n/a	RLI-AWP-	Expect	
00516	8/30/1999	Email re: Reimbursement Analysis	n/a	RLI-AWP-	Expect	
00517	8/27/1998	Judy Waterer - August 1998 Monthly	Waterer Ex. 7, 11/29/05	RoxCT0074000	Expect	
00518	2/17/2000	Email re: IVAX albuterol & Cromolyn	Feldman Ex. 90, 11/17/04	PAOLETTI07570	Expect	
00519	9/5/2003	Email re: Restructuring of US	Russillo Ex. 31, 1/8/09	RLI-AWP-	Expect	
00520	5/15/1997	Financial Statements	McIntyre Ex.15, 2/26/09	BOEH04600197	Expect	
00521	4/6/2000	Email re: Combivent UDV	Rowenhorst Ex. 6, 10/7/05	ROXCT0075126	May	
00522	10/8/1998	Email re: Private Label UDVs	n/a	RLI-AWP-	Expect	
00523	8/24/2000	Memo re: Price	Duy Ex. 45, 12/16/08	BOEH00242611	Expect	
00524	1996	1996 Budget	Waterer Ex. 78, 5/11/07	RLI-	Expect	
00525	9/20/2000	Letter re: Special Contract Pricing Opportunity Roxicodone	Ciarelli Ex.3, 7/25/07	ROX-MA-028046	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00526	TBD	Internal Distribution List--Palliative Care Field Force Communication	Ciarelli Ex. 4, 7/25/07	RLI-TX-67336	Expect	
00527	TBD	Chargebacks Standard Operating	Alesio Ex. 172, 3/3/05	RLI-TX-1673	Expect	
00528	9/14/2004	Slide Show re: BIPI Prescription Medicine Branded: Rebates and Channel	n/a	BOEH00592467	Expect	
00529	6/2/2005	Email re: June 3rd presentation - Contract Operations - CM.ppt	n/a	BOEH01018343	Expect	
00530	5/25/2001	Email re: Last Year's Annual Discussion Presentation	n/a	BOEH01660202	Expect	
00531	12/4/2002	Email re: New Doc, Attach: Roxane Functional Specifications 1b.doc	n/a	BOEH03384508	Expect	
00532	12/4/2002	Email re: New Doc	Marsh Ex. 166, 3/2/05	PAOLETTI 22549	Expect	
00533	9/1/1998	Roxane Select Multisource Agreement	n/a	RoxMA004735	Expect	
00534	4/12/2000	Email re: Medicare Reimbursement of Combivent UDV	Gordon Ex. 135, 1/25/05	ROX-TX-16237	May	
00535	11/14/2008	Defendants Roxane Responses and Objections to Plaintiff's Second	n/a	n/a	May	
00536	5/10/2000	Email re Investigators Begin Talks With Bayer on Pricing	n/a	BOEH02706018	May	
00537	2/23/1998	Email re Overpayment Information	n/a	BOEH02703121	May	
00538	8/25/2000	U.S. Subpoena, 8/25/2000	n/a	n/a	May	
00539-00580	Trial exhibit numbers 00539 through 00580 are intentionally omitted.					
00581	05/??/02	First DataBank Price Probe	n/a	FDB-AWP 01823	Expect	
00582	TBD	First DataBank	Davis Ex. 12, 8/7/08	NOV-WIS-	Expect	
00583	3/15/2000	Price Alert	Davis Ex. 15, 8/7/08	FDB-AWP-15102	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00584	12/6/1996	First DataBank National Drug Data File Standard License Agreement	Davis Ex. 17, 8/7/08	FDB/KENTUCKY03125	Expect	
00585	09/??/1991	First DataBank Monthly Interest	Davis Ex. 21, 8/7/08	FDB-AWP-28850	Expect	
00586	6/15/1999	Price Alert	Davis Ex. 26, 8/7/08	FDB-AWP-06596	Expect	
00587	TBD	First DataBank NDFF Documentation	Davis Ex. 27, 8/7/08	FDB-AWP-06295	Expect	
00588	TBD	First DataBank's Glossary of Terms	Davis Ex. 29, 8/7/08	FDB-AWP-07014	Expect	
00589	04/??/03	Glossary	Davis Ex. 31A, 8/7/08	n/a	Expect	
00590	7/9/2002	Ltr from Robert Hawley re: Alpha	Davis Ex. 35, 8/7/08	FDB-AWP-01993	Expect	
00591	7/25/2002	Ltr from Robert Hawley re July 11, 2002 Ltr to State Medicaid Directors	Davis Ex. 36, 8/7/08	FDB-AWP-01991	Expect	
00592	1994	National Drug Data File 1994	Morgan Ex. 2, 11/30/07	FDB-AWP 05345	Expect	
00593	TBD	National Drug Data File 1994	Morgan Ex. 3, 11/30/07 11/30/07	FDB-AWP 06295	Expect	
00594	TBD	Price Probe	Morgan Ex. 16, 11/30/07	FDB-AWP 10838	Expect	
00595	TBD	Depo Excerpts from Morgan 1/11/2005	Morgan Ex. 18, 11/30/07	n/a	Expect	
00596	09/??/1991	Monthly Interest--Understanding AWP	Morgan Ex. 23, 8/27/07	n/a	Expect	
00597	6/15/1999	Price Alert-- Demystifying AWP	Morgan Ex. 24, 8/27/07	n/a	Expect	
00598	5/1/2002	Email re Your Call	Morgan Ex. 25, 8/27/07	AMC00001850	Expect	
00599	5/30/2002	Letter re First DataBank Average	Morgan Ex. 26, 8/27/07	FDB-AWP-04994	Expect	
00600	7/9/2002	Letter re Alpha Therapeutic Corporation	Morgan Ex. 27, 8/27/07	FDB-AWP 04992	Expect	
00601	7/25/2002	Letter re July 11, 2002 Letter to State Medicaid Directors	Morgan Ex. 28, 8/27/07	FDB-AWP 04990	Expect	
00602	7/25/2002	Letter re July 11, 2002 Letter to State Medicaid Directors, and other letters	Morgan Ex. 6, 1/11/05	n/a	Expect	
00603	TBD	Price Alert, March 15, 2000 Issue	Morgan Ex. 7, 1/11/05	FDB-AWP-15102	Expect	
00604	TBD	Blue Book 1996	Morgan Ex. 37, 1/11/05	n/a	Expect	
00605	1990	Red Book 1990	Minne Ex. 4, 11/18/08	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00606	TBD	Red Book 1996	Minne Ex. 5, 11/18/08	n/a	Expect	
00607	9/29/1999	Red Book Product Listing Verification	Minne Ex. 7, 11/18/08	Red Book 06983	Expect	
00608	10/11/2000	Letter from Roxane re 2001 Red Book Roxane Products Listing Verification	Minne Ex. 8, 11/18/08	Red Book 14214	Expect	
00609	01/??/1999	Letter from Red Book re Help Updating Product Listings in the 2000 Red Book	Minne Ex. 13, 11/18/08	RGX 0189707	Expect	
00610	5/22/2003	Thomson's AWP Policy	Minne Ex. 17, 11/18/08		Expect	
00611	2/17/2004	Thomson's Revised AWP Policy	Minne Ex. 21, 11/18/08	Red Book 13596	May	
00612	9/18/2003	Thomson--Roxane Labs Company Pricing/Markup History	Minne Ex. 25, 11/18/08	Red Book 14160	May	
00613	TBD	Express Scripts Generic Alliance Working Document	Lyle Ex. 7, 7/22/08	CH053800	Expect	
00614	6/1/1995	Slide show: The Power of a Partnership with Cardinal Health	Lyle Ex. 8, 7/22/08	ABT005762	Expect	
00615	3/15/1993	DMERC Region Map	n/a	DL-TX-0075978	Expect	
00616	01/??/1998	Transmittal AB-97-25	n/a	HHD051-0291	Expect	
00617	12/??/1998	HCFA transmittal AB-98-76	n/a	HHC021-0030	Expect	
00618	11/14/2000	Transmittal AB-00-110	n/a	n/a	Expect	
00619	TBD	CIGNA Government Services Ipratropium Bromide Arrays	n/a	AWQ021-0097	Expect	
00620	TBD	CIGNA Government Services	n/a	AWQ039-0044	Expect	
00621	TBD	Listing of CIGNA Government Services Ipratropium Bromide arrays	n/a	n/a	Expect	
00622	TBD	CIGNA Government Services arrays	n/a	AWQ020-000887	Expect	
00623	TBD	Red Book printouts	n/a	AWP038--1462	Expect	
00624	TBD	CIGNA Government Services arrays for	n/a	AWQ039-0025	Expect	
00625	2009	Exhibit Abbott 522	Abbott Ex. 522, 2/28/08	n/a	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00626	TBD	Palmetto Arrays for Ipratropium	n/a	n/a	Expect	
00627	TBD	Palmetto Albuterol Arrays J7620	n/a	n/a	Expect	
00628	TBD	Palmetto Albuterol Arrays K0505 J7619	n/a	n/a	Expect	
00629	08/??/08	Deposition exhibit Eiler Ex. 5	Eiler Ex. 5, 9/23/08	n/a	Expect	
00630	TBD	Deposition exhibit Eiler Ex. 7	Eiler Ex. 7, 9/23/08	n/a	Expect	
00631	2008	Deposition exhibit Eiler Ex. 9	Eiler Ex. 9, 9/23/08	n/a	Expect	
00632	TBD	AdminaStar Federal Ipratropium arrays	n/a	n/a	Expect	
00633	TBD	AdminaStar Federal Albuterol Arrays	n/a	n/a	Expect	
00634	2009	Exhibit A to Declaration of Colleen M. King dated 2/2/2009	n/a	n/a	Expect	
00635	TBD	Travelers Insurance Company Albuterol Arrays J7619	n/a	n/a	Expect	
00636	TBD	Red Book For Windows	Helton Ex. 265, 10/16/09	n/a	Expect	
00637	12/15/1999	DMERC Medication Pricing Array, CIGNA Government Services	Helton Ex. 262, 10/16/09	CIGNA-0101	Expect	
00638	10/??/00	Red Book for Windows, Detailed Product Information	Helton Ex. 256, 10/16/09	n/a	Expect	
00639	11/2/1998	Federal Register, 63 FR Federal Register, Vol 63, No 211, Rules and Regulations, Monday Nov 2, 1998	n/a	58849	Expect	
00640	10/??/00	Red Book for Windows, Detailed Product Information	Helton Ex. 257, 10/16/09	n/a	Expect	
00641	TBD	Red Book for Windows, Detailed Product Information	Helton Ex. 266, 10/16/09	n/a	Expect	
00642	1999	DMERC Medicare DMERC Medicaid Advisory--Issue 29, Summer 1999,	n/a	n/a	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00643	6/5/1998	63 FR Federal Register Vol 63, No. 108, Proposed Rule	n/a	30846	Expect	
00644	10/??/00	Red Book for Windows, Detailed Product Information	Stone ex. 258, 10/14/09	n/a	Expect	
00645	TBD	Ex. C. to Declaration of Robin Stone dated 7/23/2009	n/a	AWQ025	Expect	
00646	09/??/1999	Program Memorandum Intermediaries/Carriers, Transmittal AB-	n/a	n/a	Expect	
00647	5/22/2002	Transmittal AB-02-075	n/a	n/a	May	
00648	TBD	Exhibit E to Expert Report of Simon Platt	n/a	n/a	Expect	
00649	TBD	Exhibit F to Expert Report of Simon Platt	n/a	n/a	Expect	
00650	TBD	Exhibit G to Expert Report of Simon Platt	n/a	n/a	Expect	
00651	TBD	Exhibit H to Expert Report of Simon Platt	n/a	n/a	Expect	
00652	TBD	Graphs 1-3 to Expert Report of Simon	n/a	n/a	Expect	
00653	TBD	Graphs & Summaries A1-A13 to Expert Report of Simon Platt (Dey)	n/a	n/a	Expect	
00654	TBD	Dey Direct (Summaries 1-4) to Expert Report of Simon Platt (Dey)	n/a	n/a	Expect	
00655	TBD	Dey Direct Average Price Calculations (Summary 5) to Expert Report of Simon	n/a	n/a	Expect	
00656	TBD	Dey - Direct Average Price Calculations (Summary 6) to Expert Report of Simon	n/a	n/a	Expect	
00657	TBD	Dey InDirect (Summaries 7-10) to Expert Report of Simon Platt (Dey)	n/a	n/a	Expect	
00658	TBD	Dey - Indirect Average Price Calculations (Summary 11) to Expert Report of Simon	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00659	TBD	Dey - Indirect Average Price Calculations (Summary 12) to Expert Report of Simon	n/a	n/a	Expect	
00660	TBD	Exhibit E to Expert Report of Simon Platt	n/a	n/a	Expect	
00661	2/6/2009	Graphs 1-17 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00662	7/21/2009	Graphs & Summaries A1-A10 to Declaration of Simon Platt (Roxane)	n/a	n/a	Expect	
00663	2/6/2009	Summaries 1-4 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00664	2/6/2009	Summary 5 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00665	2/6/2009	Summary 6 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00666	Exhibit Number 666 Intentionally Omitted					
00667	2/6/2009	Summaries 7-10 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00668	2/6/2009	Summary 11 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00669	2/6/2009	Summary 12 to Expert Report of Simon Platt (Roxane)	n/a	n/a	Expect	
00670	07/??/09	Myers & Stauffer Medicaid Reimbursement Methodology Summaries (Declaration Attachment 1)	n/a	n/a	Expect	
00671	TBD	Attachment 2 to Declaration of Myers		n/a	Expect	
00672	TBD	Attachment 3 to Declaration of Myers	n/a	n/a	Expect	
00673	TBD	Attachment 4 to Declaration of Myers	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00674	1/23/2009	Duggan Report (Dey) Figure 1A: Dey's First DataBank AWP and WAC versus Dey's Direct Avg Price for Alb Sulf	n/a	n/a	Expect	
00675	1/23/2009	Duggan Report (Dey) Figure 1B: Dey's First DataBank AWP and WAC vs. Dey's Direct Avg Price for Ipra Brom	n/a	n/a	Expect	
00676	1/23/2009	Duggan Report (Dey) Figure 2A Dey's First DataBank AWP	n/a	n/a	Expect	
00677	1/23/2009	Duggan Report (Dey) Figure 2B Dey's First Data Bank AWP and WAC	n/a	n/a	Expect	
00678	1/23/2009	Duggan Report (Dey) Tables 1 - 5, Dey Direct Transaction Data	n/a	n/a	Expect	
00679	1/23/2009	Duggan Report (Dey) Table 6 -Table 10 Dey Indirect Transaction Data 1992-	n/a	n/a	Expect	
00680	1/23/2009	Duggan Report (Dey) Table 11-Table 12C Comparison of Dey CMS State Drug	n/a	n/a	Expect	
00681	1/23/2009	Duggan Report (Dey) Table 13A -Table 13D Breakdown of NY Medicaid	n/a	n/a	Expect	
00682	1/23/2009	Duggan Report (Dey) Table 14A-Table 14B Breakdown of CA Medicaid	n/a	n/a	Expect	
00683	1/23/2009	Duggan Report (Dey) Table 15A -Table 15C Breakdown of FL Medicaid Spending	n/a	n/a	Expect	
00684	1/23/2009	Duggan Report (Dey) Table 16A -Table 26D Breakdown of Multiple States	n/a	n/a	Expect	
00685	1/23/2009	Duggan Report (Dey) Table 27 - Medicaid Summary for First Fourteen	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00686	1/23/2009	Duggan Report (Dey) Table 28A -Table 28C Spending and Utilization for other 33 states and D.C.	n/a	n/a	Expect	
00687	1/23/2009	Duggan Report (Dey) Table 29A -Table 29B Medicaid Summary for Next 17	n/a	n/a	Expect	
00688	1/23/2009	Duggan Report (Dey) Table 30 -Table 34 Summary of Dey Medicare	n/a	n/a	Expect	
00689	1/23/2009	Duggan Report (Dey) Table 35 - Summary of Medicare DME Ipratropium	n/a	n/a	Expect	
00690	1/23/2009	Duggan Report (Dey) Table 36 Number of Medicaid Reimbursed Ipratropium Presc. by Firm & NDC	n/a	n/a	Expect	
00691	1/23/2009	Duggan Report (Dey) Table 35 & Table 37 Summary of Medicare DME - Ipratropium & Albuterol Results	n/a	n/a	Expect	
00692	2/25/2009	Duggan Supplemental Report (Dey) Table 38A Dey/Roxane Combined with	n/a	n/a	Expect	
00693	2/25/2009	Duggan Supplemental Report (Dey) Table 38B Dey/Roxane Combined with	n/a	n/a	Expect	
00694	4/23/2009	Duggan Rebuttal (Dey) Figure A & B Data source by Year by Medicaid Claims &	n/a	n/a	Expect	
00695	4/23/2009	Duggan Rebuttal (Dey) Table A Dey Ipratropium Bromide: Difference by	n/a	n/a	Expect	
00696	4/23/2009	Duggan Rebuttal (Dey) Table B - Dey Albuterol: Difference by DMERC and	n/a	n/a	Expect	
00697	2/9/2010	Duggan Declaration Exhibit 1 - Average Paid Amount Per Unit	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00698	TBD	Duggan Declaration Exhibit 2 - FL FMMIS Claims showing lesser-of Methodology	n/a	n/a	Expect	
00699	2/5/2010	Confidence Interval of the Estimate, with State Effects	n/a	n/a	Expect	
00700	TBD	Duggan Report (Roxane) Figure 1 Roxane's FBD AWP & WAC vs. Roxane's Direct Avg Price for Ipra Brom	n/a	n/a	Expect	
00701	TBD	Duggan Report (Roxane) Figure 2: Roxane's First DataBank AWP and WAC vs. Indirect Avg Price for Pharmacy COTs	n/a	n/a	Expect	
00702	2/6/2009	Duggan Report (Roxane) Tables 1 -5 Roxane Direct Transaction Data	n/a	n/a	Expect	
00703	2/6/2009	Roxane Tables 6-10 Roxane Indirect Transaction Data	n/a	n/a	Expect	
00704	2/6/2009	Duggan Report, Roxane Tables 11A-12B Medicaid Spending on Roxane	n/a	n/a	Expect	
00705	2/6/2009	Duggan Report, Roxane Tables 13A-13C Breakdown of CA Medicaid Spending	n/a	n/a	Expect	
00706	2/6/2009	Duggan Report, Roxane Tables 14A-14B Breakdown of FL Medicaid Spending	n/a	n/a	Expect	
00707	2/6/2009	Duggan Report, Roxane Tables 15A-15B Breakdown of NY Medicaid Spending	n/a	n/a	Expect	
00708	2/6/2009	Duggan Report, Roxane Tables 16A-28B Breakdown of Various States Medicaid	n/a	n/a	Expect	
00709	2/6/2009	Duggan Report, Roxane Table 29 Medicaid Summary for First Sixteen	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00710	2/6/2009	Duggan Report, Roxane Tables 30A-30C SMRF-MAX Spending & Utilization of other 32 states & DC	n/a	n/a	Expect	
00711	2/6/2009	Duggan Report, Roxane Tables 31A-31B Medicaid Summary for Next 17 states	n/a	n/a	Expect	
00712	2/6/2009	Duggan Report, Roxane Tables 32-36 Summary of Roxanne Medicare DME	n/a	n/a	Expect	
00713	2/6/2009	Duggan Report, Roxane Table 37rev Summary of Medicare DME Ipratropium	n/a	n/a	Expect	
00714	2/6/2009	Duggan Report, Roxane Table 38 Number of Medicaid Reimbursement	n/a	n/a	Expect	
00715	2/6/2009	Duggan Report, Roxane Table 39A Dey/Roxane Combined with NovaPlus	n/a	n/a	Expect	
00716	2/6/2009	Duggan Report, Roxane Table 39B Dey/Roxane Combined, No NovaPlus	n/a	n/a	Expect	
00717	4/23/2009	Duggan Rebuttal (Roxane) Figures A&B Data Source by Number and Paid by	n/a	n/a	Expect	
00718	4/23/2009	Duggan Rebuttal (Roxane) Table A Roxane Ipratropium Bromide; Diffs by	n/a	n/a	Expect	
00719	2/5/2010	Duggan (Roxane) Confidence Interval of The Estimate, with State Effects	n/a	n/a	Expect	
00720	TBD	NDDF User's Manual--Appendix G re: Average Wholesale Price	n/a	n/a	Expect	
00721	12/7/2004	Excerpts from Serial No. 108-126, Medicaid Prescription Drug Reimbursement: Why the Government	n/a	n/a	May	
00722	TBD	First DataBank definitions	n/a	n/a	Expect	

The United States' Exhibit List

Trial Exhibit #	Date of Document	Title or Brief Description	Depo Exhibit -deponent name, depo Ex. #, date of depo	Beginning Bates #	Intent to Offer	Objection
00723	TBD	Account Call Record, William Hill Ex. 21A	Hill Ex. 21A, 11/11/08	DEY-OIG-0125371	May	
00724	10/1/2001	September 2001 Sales Reports	Mozak Ex. 241, 4/30/02	DL-TX-0078133	May	
00725	1997	Executive Summary American Drug	Tate Ex. 472, 2/7/03	DL-TX-0004782	May	
00726	7/21/2009	Ex. A to Declaration of Ian Dew dated	n/a	n/a	Expect	
00727	7/21/2009	Ex. B. to Declaration of Ian Dew dated	n/a	n/a	Expect	
00728	7/21/2009	Ex. C to Declaration of Ian Dew dated	n/a	n/a	Expect	
00729	7/21/2009	Ex. D to Declaration of Ian Dew,	n/a	n/a	Expect	
00730	12/??/01	Ltr from Robert Mozak re Notice of Price	n/a	DEY-FLA-0125561	May	
00731	2/11/1991	Letter from Pamela Marrs to HCFA re Rebate Agreement	Marrs Ex. 28, 7/10/08	DEY-BO-0226957	Expect	
00732	6/19/2008	Defendants Dey Responses and Objections to Plaintiff's First Set of	Marrs Ex. 32, 7/10/08	n/a	Expect	
00733	1/3/2008	United States' First Amended Cross-Notice of Deposition of Dey	Marrs Ex. 1, 5/15/08	n/a	Expect	
00734	5/5/2003	Federal Register, Vol 68, No 86, Notices, page 23731	Marrs Ex. 38, 10/2/08	n/a	Expect	
00735	1/31/1996	McKesson Drug Company--Source Program Proposal	Marrs Ex. 64, 10/2/08	DL-TX-0031294	Expect	
00736	4/15/2003	Declaration of Russell Johnston	n/a	n/a	Expect	
00737	3/15/2010	Summary entitled "Dey-Roxane DME Allowed Unit Amounts DMERC A Trav	n/a	n/a	Expect	
00738	3/15/2010	Summary entitled "Units of K0518 and J7644 per Quarter in DME Paid Claims with Different Unit Allowed Amounts by	n/a	n/a	Expect	
00739	3/15/2010	Summary entitled "Units of K0518 and J7644 per Quarter in DME Paid Claims with Different Unit Allowed Amounts by	n/a	n/a	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00740	3/16/2010	Dey-Roxane DMERC Array Gaps and Summaries of RedBook published data	n/a	n/a	Expect	
00741	3/16/2010	Summary of AWP prices reported to FDB for Ipratropium Bromide .02%, 2.5 ml.	n/a	n/a	May	
00742	10/14/2000	Ltr from Walker to Neimann re CIGNA Part B Medicare	n/a	AWP-CD-104	May	
00743 - 00749	Trial exhibit numbers 00743-00749 are intentionally omitted.					
00750	11/6/2008	AR Medicaid Pharmacy Reimbursement Methodology, Draft	Bridges Ex. 3, 12/10/08	n/a	May	
00751	8/24/2007	CA Section 14105.45	Gorospe Ex. 4, 3/19/08	n/a	Expect	
00752	6/20/1997	Ltr from HHS to Joe Kelly of Medi-CAL	Gorospe Ex. 5, 12/3/08	CAAG/DHS00683	Expect	
00753	3/19/1991	Ltr Re: Approval of California SPA 89-08 relating to payments for prescription	Gorospe Ex. 13, 12/3/08	CAAG/DHS 0013323	Expect	
00754	9/22/1989	Ltr Re: CA EAC Program for payment of drug products	Gorospe Ex. 14, 12/3/08	HHC016-0830	Expect	
00755	5/20/1993	CA State Plan Under Title XIX of Social	Gorospe Ex. 15, 12/3/08	CAAG/DHS	Expect	
00756	2/1/1995	Ltr Re: Approved Copy of CA State Plan Amendment (SPA) 94-015, regarding reimbursement for prescribed drugs	Gorospe Ex. 16, 12/3/08	CAAG/DHS 0022500	Expect	
00757	1/??/1992	Title 22, CA Code of Regulations	Gorospe Ex. 17, 12/3/08	CAAG/DHS00316	Expect	
00758	6/??/2002	Survey of Acquisition Costs of Pharmaceuticals in the State of CA	Gorospe Ex. 21, 12/3/08	n/a	Expect	
00759	9/30/2002	Assembly Bill No. 442, Ch. 1161	Gorospe Ex. 22, 12/3/08	n/a	Expect	
00760	11/??/2002	Medi-Cal Update, Billing and Policy Pharmacy Bulletin 546	Gorospe Ex. 23, 12/3/08	CAAG/DHS00343 75	Expect	
00761	1/2/2004	Ltr Re: CA State Plan Amendment (SPA)	Gorospe Ex. 24, 12/3/08	CAAG/DHS	Expect	



The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00762	2008	CA Welfare & Institution Code 14105.45 - Definitions	Gorospe Ex. 25, 12/3/08	n/a	Expect	
00763	1/3/2005	Ltr Re: CMS approved CA's State Plan Amendment (SPA) 04-010	Gorospe Ex. 26, 12/3/08	CAAG/DHS 0028969	Expect	
00764	TBD	Reimbursement Methodology Chart addressing EAC and	Parker Ex. 3, 11/18/08	n/a	Expect	
00765	TBD	Summary of IL Medicaid Providers	Parker Ex. 11, 11/18/08	n/a	Expect	
00766	03/??/1994	Medicaid Pharmacy Payments AAC & EAC by the MI Dept. of Social Services	Abbott 657	n/a	Expect	
00767	7/18/2000	Ltr Re: New Albuterol Inhalation Aerosol	Dey Ex. 124	DEY MDL 0105083-	May	
00768	2/9/2007	US Complaint as to Roxane	Vaccaro Ex. 9, 12/2/2008	n/a	Expect	
00769	9/29/2008	US First Amended Complaint as to Dey	Vaccaro Ex. 8, 12/2/2008	n/a	Expect	
00770	TBD	Graph, Dey Indirect Transaction Data	Butt Ex. 54, 2/12/10	n/a	Expect	
00771	TBD	Graph, Roxane Indirect Transaction Data	Butt Ex. 56, 2/12/10	n/a	Expect	
00772	3/16/1999	Ltr Re: Price Change for EpiPen and EpiPen Jr.	Butt Ex. 40, 2/12/10	NYCO AWP NYDOH 03203	Expect	
00773	7/3/2000	Email Re: Medicaid	Butt Ex. 20, 2/12/10	NYCO AWP NYDOH 13620	Expect	
00774	9/??/2002	Notice of Price Change Re: Dey Increasing the AWP of selected drugs	Butt Ex. 57, 2/12/10	NYCO AWP NYDOH 01878	Expect	
00775	5/13/1992	Ltr Re: SPA #92-08	Hautea-Wimpee-DOJ Ex. 24, 12/2/2009	HHC016-0586	May	
00776	7/11/1996	Memo Re: Review of Pharmacy Acquisition Costs for Drugs Reimbursed Under the Medicaid Prescription Drug	Homar-Rox Ex. 3, 12/2/08	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00777	3/14/2002	Memo Re: Medicaid Pharmacy - Actual Acquisition Cost of Generic Prescription	Homar-Rox Ex. 5, 12/2/08	n/a	May	
00778	8/22/2006	Email Re: WY - July AMP Data Analysis	Homar Ex. 3, 12/3/08	WY00000870	May	
00779	6/3/2008	WY Medicaid Pharmacy Reimbursement Methodology	Homar Ex. 1, 12/3/08	n/a	Expect	
00780	TBD	Medicaid Program Budget Report State Estimate of Quarterly Grant Awards	n/a	n/a	Expect	
00781	TBD	Quarterly Medicaid Statement of Expenditures for the Medical Assistance	n/a	n/a	Expect	
00782	TBD	Chart - Politics of Medicaid and	n/a	n/a	May	
00783	TBD	Chart - Medicaid Prescription Drug Spending 1966-2003	n/a	n/a	May	
00784	TBD	Chart - Medicaid Drug Spending as a Percentage of Total Medicaid Spending	n/a	n/a	May	
00785	TBD	Chart - Medicare Spending	n/a	n/a	May	
00786	TBD	Chart - Medicare Pt. B Drug Spending	n/a	n/a	May	
00787	TBD	Summary Chart of Dey Internal Company Documents	n/a	n/a	Expect	
00788	TBD	Summary Chart of Roxane Internal Company Documents	n/a	n/a	Expect	
00789	12/13/1977	Transmittal, HCFA-AT-77-113 (MMB) in	n/a	n/a	May	
00790	3/??/1993	FDB - National Drug Data File, "The Most Comprehensive Drug Database"	n/a	n/a	May	
00791	5/30/2002	Ltr from Robert Hawley, Hearst Publishing to Alpha Therapeutic Corp.	n/a	n/a	May	
00792	7/??/2000 - 8/??/2000	FDB - "Medicaid Reimbursement Pricing Issues"	n/a	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00793	10/15/2000	Pharmacy Times - "Just the Facts, Generic Rx Product Report"	n/a	n/a	May	
00794	4/7/2009	Rx Watchdog Report - Trends in Manufacturer Prices of Prescription Drugs Used by Medicare Beneficiaries	n/a	n/a	May	
00795	3/4/1996	Memo from Todd Galles to Territory Account Managers	n/a	EXP SCH DEY/ROX 002362	Expect	
00796	Fall 1996	Ipratroprium Bromide Launch Manual	n/a	EXP SCH DEY/ROX 005386	Expect	
00797	4/5/1995	Memo Re: Attached Incentive Information	n/a	EXP SCH DEY/ROX 000471	Expect	
00798	2/24/1992	Memo Re: Albuterol Pricing Strategies	n/a	EXP SCH DEY/ROX 000001	Expect	
00799	5/30/1995	Memo from Dey "Medicaid Rx Reimbursement Report, Drug Topics"	n/a	n/a	Expect	
00800	8/30/2004	Medicaid and Medicare Drug Pricing: Strategy to Determine Market Prices	n/a	n/a	May	
00801	11/16/1998	Nam Kar Confidential Pricing	n/a	RLI-AWP-	Expect	
00802	5/23/2002	Roxane Laboratories, Inc. – Contract Pricing Template	n/a	BOEH01054133	Expect	
00803	12/??/2000	Dey Average Price – Eaches	n/a	EXP SCH DEY/ROX 004656	Expect	
00804	12/??/2000	Dey Average Price – Shelf Cartons	n/a	EXP SCH DEY/ROX 004653	Expect	
00805	7/??/1995 - 8/??/1995	Dey Bid Reports	n/a	EXP SCH DEY/ROX 004667	Expect	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00806	3/14/2002	Statement of Thomas A. Scully Re: reimbursement/access to drugs, 2002	n/a	n/a	May	
00807	2002	Channels of Distribution for Prescription Drugs: 2002	n/a	n/a	May	
00808	2002	Sources of Payment for Prescription	n/a	n/a	May	
00809	9/26/1995	Ltr from Rep. Stark to DHHS Secretary	n/a	VAC MDL 64629	May	
00810	6/24/1997	H.R. Rep. 105-149 at 1354	n/a		May	
00811	11/5/1997	Ltr from Nancy Ann DeParle to Rep.	n/a	VAC MDL 64483	May	
00812	12/15/1997	Ltr from Rep. Stark to June Gibbs Brown	Roxane Ex. 12	HHD009-0281	May	
00813	01/26/1998	Ltr sent to Rep. Stark from Nancy Ann	Abbott Ex. 205	HHC001-0363	May	
00814	6/3/1998	Ltr from Rep. Stark to Nancy Ann	n/a	VAC MDL 64334	May	
00815	4/21/1999	Ltr from Rep. Stark to Nancy Ann	n/a	VAC MDL 64259	May	
00816	1999	DHHS Report to Congress on the AWP for Drugs Covered Under Medicare	Abbott Ex. 200	HHC902-0801	May	
00817	05/05/2000	Ltr from Rep. Bliley to Shalala	Abbott Ex. 212	n/a	May	
00818	05/31/2000	Ltr from Shalala to Rep. Bliley	n/a	VAC MDL 70623	May	
00819	06/30/2000	Dey Ltr to Rep. Bliley	n/a	VAC MDL 53692	May	
00820	09/28/2000	Ltr from Rep. Pete Stark to PhRMA	n/a	VAC MDL 64099	May	
00821	10/09/2000	Ltr from PhRMA to Rep. Stark	n/a	VAC MDL 64828	May	
00822	7/21/2001	Testimony of Scully to House Energy and Commerce Subcommittees on Oversight and Investigations and Health Re: Medicare Payment for Drugs	Abbott Ex. 183	n/a	May	
00823	11/22/2000	Ltr from Rep. Stark to Rep. Bliley	n/a	VAC MDL 64875	May	
00824	10/3/2002	H.R. Rep. 107-84	Abbott 191	n/a	May	
00825	7/15/2003	H.R.Rep. No. 108-178, pt. 2, at 194	n/a	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00826	TBD	42 U.S.C. § 1396r-8(e) - OBRA 1990, Pub. L. 101-239, Sec. 4401(a)(3).	n/a	n/a	May	
00827	TBD	42 C.F.R § 405.500	n/a	n/a	May	
00828	TBD	42 C.F.R. § 405.517	n/a	n/a	May	
00829	TBD	42 C.F.R. § 447.331	n/a	n/a	May	
00830	TBD	42 C.F.R. § 447.301	Chapman Ex. 3, 12/15/08	n/a	May	
00831	7/17/1968	33 Fed. Reg. 10233	n/a	n/a	May	
00832	1/25/1969	34 Fed. Reg. 1244	n/a	n/a	May	
00833	11/15/1974	39 Fed. Reg. 40302	n/a	n/a	May	
00834	11/27/1974	39 Fed. Reg. 41480	n/a	n/a	May	
00835	7/31/1975	40 Fed. Reg. 32284	n/a	n/a	May	
00836	8/15/1975	40 Fed. Reg. 34516	n/a	n/a	May	
00837	8/19/1986	51 Fed. Reg. 29560	n/a	n/a	May	
00838	9/7/1989	54 Fed. Reg. 37208	n/a	n/a	May	
00839	6/5/1991	56 Fed. Reg. 25792	n/a	n/a	May	
00840	06/05/1991	56 Fed. Reg. No. 108, Proposed Rules	Abbott 1021	n/a	May	
00841	11/25/1991	56 Fed. Reg. 59502-01, 42 CFR Parts 405, 413, and 415	Abbott 301	n/a	May	
00842	11/25/1991	56 Fed. Reg. No. 227	Abbott 1020	n/a	May	
00843	01/07/1998	63 Fed. Reg. No 4	Abbott 210	HHC001-0606	May	
00844	08/20/2003	Fed. Reg. Re: 42 CFR Part 405 Medicare Program; Payment Reform for Part B	Abbott 1023	n/a	May	
00845	11/07/2003	68 Fed. Reg. No. 216, Rules and Regulations Re: DHHS, CMS Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for	Abbott 1016	n/a	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00846	01/07/2004	Fed. Reg. Part IX, Department of Health and Human Services, CMS 42 CFR Parts	Abbott 1022	n/a	May	
00847	04/06/2004	69 Fed. Reg. No. 66	Abbott 1017	n/a	May	
00848	12/13/1977	HHS Action Transmittal, HCFA-AT-77-113	n/a	n/a	May	
00849	9/??/1984	Medicaid Action Transmittal 84-12	Abbott 269	HHC011-2200	May	
00850	09/??/1984	Medicaid Action Transmittal 84-12	Abbott 78	HHC011-0513	May	
00851	10/??/1992	HCFA Transmittal No. 21	n/a	HHD170-0499	May	
00852	09/??/1999	Program Memorandum Intermediaries/Carriers, DHHS, HCFA Report with Transmittal No. AB-99-63	Abbott 1006	HHD084-0665	May	
00853	9/8/2000	Program Memo, Intermediaries Carriers Transmittal AB-00-86, Change Request	Roxane 55	AWP020-0199	May	
00854	11/17/2000	Program Memo AB-00-115	n/a	HHD004-0022	May	
00855	01/18/2001	Program Memo Intermediaries/Carriers DHHS, HCFA Transmittal No AB-01-04, Change Request 1441	Abbott 1009	HHD007-0001	May	
00856	05/03/2001	Program Memo Intermediaries/Carriers DHHS, HCFA Transmittal No AB-01-66, Change Request 1653	Abbott 1010	HHD014-0207	May	
00857	12/03/2002	Program Memo Intermediaries/Carriers DHHS, HCFA Transmittal No. AB-02-174, Change Request 2381	Abbott 1012	HHC014-0201	May	
00858	02/07/2003	Program Memo Intermediaries/Carriers DHHS, HCFA Transmittal No. AB-03-014, Change Request 2544	Abbott 1013	n/a	May	
00859	01/31/1991	Memo from HCFA Region III to HCFA HQ	n/a	AWQ046-0003	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00860	03/15/1994	Faxed Memo From Director To All Associate Regional Administrators for	Roxane 105/ Dey 110	AWP010-1339	May	
00861	3/22/1994	Ltr All Region II Re: Determination of Acquisition Cost	Abbott 304	AWP041-0823	May	
00862	6/8/1994	Ltr All Regional Carriers Re: Determination of Cost of Drugs -- Action	Roxane 44	n/a	May	
00863	8/12/1994	Memo from HCFA to All Associate Regional Administrators	n/a	AWP032-0035	May	
00864	9/6/1994	State Medicaid Regional Bulletin No. 94-	n/a	HHC006-0428	May	
00865	9/23/1994	State Medicaid Regional Memo 94-63	n/a	ATP083-3128	May	
00866	TBD	HHS State Medicaid Manual 6305 -	n/a	n/a	May	
00867	TBD	HHS State Medicaid Manual 6305.1	n/a	n/a	May	
00868	7/3/1990	HCFA letter to TX, Re: Medicare Pricing	Abbott 294	HHC906-0093	May	
00869	10/24/1991	HCFA letter to Hawaii, Re: SPA	n/a	HHC016-0603	May	
00870	8/25/1993	NTIS Report Re: Assessment of Adequacy of Reimbursement Rates to	n/a	ATP107-0223	May	
00871	1994	Article Re: State Medicaid Pharmacy Payment and Relation to Estimated	n/a	n/a	May	
00872	7/21/1994	Alleged Paperwork Violation	Abbott 364	n/a	May	
00873	9/15/1994	State Agency Letter Number 94-43	n/a	HHC019-0150	May	
00874	12/05/1997	Memo from June Gibbs Brown to	Abbott 002A	HHD009-0258	May	
00875	12/15/1997	Westlaw Pub. Re: The White House Office of Communications, Re: Weekly Radio Address to the Nation 12/13/97	Abbott 156	n/a	May	
00876	03/02/1998	Fax from Maureen Adolph to Rob Vito	Abbott 203	HHD042-0319	May	
00877	06/??/1998	Ltr Re: Prescription Drug Assurances for Compliance with 42 CFR 447.332	Roxane 20	HHC011-2260	May	

The United States' Exhibit List

<b>Trial Exhibit #</b>	<b>Date of Document</b>	<b>Title or Brief Description</b>	<b>Depo Exhibit -deponent name, depo Ex. #, date of depo</b>	<b>Beginning Bates #</b>	<b>Intent to Offer</b>	<b>Objection</b>
00878	12/07/1999	Email from Paoletti to Rowenhorst	n/a	BOEH03386435	May	
00879	3/7/2000	Email from Kay Morgan at First DataBank to R. Feldman at BI forwarding	n/a	RLI-AWP-00000435	May	
00880	9/8/2000	Internal Roxane memo by Shaffer regarding reimbursement	n/a	RLI-AWP-00083482	May	
00881	8/24/2001	Cover Sheet: OIG Draft - Medicaid Pharmacy - Actual Acquisition Cost of Generic Prescription Drug Products	Abbott 370	HHC004-0222	May	
00882	7/26/2002	Fax & HCFA Release No. 48	n/a	HHD346-0001	May	
00883	12/2/2002	Pharmaceutical Mfrs Ltr to IG, Re: Draft OIG Compliance Guidance	n/a	n/a	May	
00884	4/22/2004	Ltr from CMS Approving SPA for NH	Dey 95	NH00092	May	
00885	9/29/1989	OIG Report A-06-89-00037	n/a	n/a	May	
00886	06/??/1996	OIG Report OEI-03-94-00393	Abbott 30	HHD014-0254	May	
00887	02/??/1996	OIG Report OEI-03-94-00390	Abbott 59	HHD008-0407	May	
00888	05/??/1996	OIG Report OEI-03-95-00420	Abbott 102	n/a	May	
00889	06/??/1996	OIG Report OEI-03-94-00392	Abbott 60	n/a	May	
00890	06/??/1996	OIG Report OEI-03-94-00393	Abbot 30	HHD014-0254	May	
00891	12/??/1997	OIG Report OEI-03-97-00290	Abbott 49	HHD014-0023	May	
00892	7/??/1998	OIG Report OEI-03-97-00510	Abbott 1004	n/a	May	
00893	08/??/1998	OIG Report OEI-03-97-00292	Abbott 64	n/a	May	
00894	11/??/1998	OIG Report OEI-03-97-00293	Roxane 159	n/a	May	
00895	01/??/2001	OIG Report OEI-03-00-00310	Abbott 1005	n/a	May	
00896	09/??/1996	OIG Report OEI-03-94-00392	Dey 613	HHD014-0235	May	
00897	1998	CMS Financial Management Report FY 19	n/a	n/a	Expect	